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ABSTRACT OF THE DISSERTATION
THE EFFECT OF THE TYG INDEX ON LIVER STEATOSIS, IMMUNE
ACTIVATION, OXIDATIVE STRESS, LIVER FIBROSIS PATHWAYS AND
LIVER FIBROSIS IN THE MIAMI ADULT STUDIES ON HIV (MASH) COHORT
by
Colby S. Teeman
Florida International University, 2021
Miami, Florida
Professor Marianna Baum, Major Professor

The purpose of this study was to establish the Triglyceride-Glucose (TyG)
Index Ln (fasting TG x fasting glucose/2) as a predictor of liver steatosis in
People Living with HIV (PLWH) and determine the effect of increased TyG Index
on biomarkers of immune activation, inflammation, oxidative stress, apoptosis,
and liver fibrosis. Four-hundred and eighty participants were selected from the
Miami Adult Studies on HIV (MASH) cohort, two-hundred and eleven were
PLWH, and two-hundred and sixty-nine were uninfected controls. Biomarkers
were analyzed from blood samples collected at the FIU Borinquen Clinic. Primary
research outcomes were analyzed using multiple linear and logistic regression,
pairwise analyses, and ROC curves.
The TyG Index was determined to be a good predictor of liver steatosis
among PLWH and uninfected controls (AUC=0.738 and AUC=0.702),
respectively. Participants in the High TyG Risk category were 4.638 times more
likely to have liver steatosis than those in the Low TyG Risk category [95%
CI:(2.075, 10.368)]. Greater TyG Index was associated with higher immune
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activation markers Ln sCD14 (β=0.080, P=0.050) and Ln sCD163 (β=0.164,
P=0.008). Linear regression analysis found HIV infection to be associated with
higher levels sCD27 (β=0.181, P=0.005), and liver fibrosis pathway biomarkers
Ln TGF- β (β=0.915, P<0.001) and Ln TIMP-1 (β = 0.118, P=0.034). Dietary
saturated fat intake was associated with increased hepatic apoptosis (β = 3.26,
P=0.050). Linear regression analysis indicated HIV infection was associated with
decreased Free GSH (β = -95.24, P=0.003) and decreased Total GSH (β= 93.60, P=0.003), indicating higher oxidative stress. Logistic regression analysis
adjusted for Age, Sex, BMI, HIV Infection, and Cocaine Use, showed greater
TyG Index was associated with greater likelihood of liver fibrosis in PLWH only
[OR= 1.783 (1.114, 2.855), P=0.016] and all MASH Cohort participants
[OR=1.244 (0.914, 1.692), P=0.046].
These data indicate a consistent relationship between increased TyG
Index and biological pathways that lead to liver fibrosis. As liver disease
becomes a more prominent concern among PLWH, it is crucial for health care
professionals to address markers of metabolic health, such as the TyG Index, as
a means to effectively manage liver steatosis and avoid the development of liver
fibrosis.
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Chapter I: INTRODUCTION
STATEMENT OF PROBLEM
There are greater than one-million people living in the United States with
HIV infection and nearly forty-million around the world.1 In recent decades,
antiretroviral therapy (ART) has increased the rate of controlled HIV viral load
(VL) and helped people living with HIV (PLWH) maintain higher CD4+ cell counts,
thus resulting in increased life expectancy of PLWH.2 Lower HIV VL and higher
CD4+ cell counts have resulted in a decrease in AIDS related events.3 Reduced
AIDS mortality and chronic exposure to ART have led to an increase in chronic
diseases commonly seen in the general population; including cardiovascular
disease, diabetes, hyperlipidemia, hypertension, and obesity.4 Of particular
interest to this work is the relationship between HIV and liver disease, PLWH are
3.7x more likely to die of liver disease than the general population.5 Nonalcoholic fatty liver disease (NAFLD), also known as liver steatosis, is the most
common liver disease in the world.6 Between 5-10% of individuals with NAFLD
will develop non-alcoholic steatohepatitis (NASH) and 38% of these individuals
will develop liver fibrosis.7 The prevalence of NAFLD in PLWH has been reported
at 35% around the world,8 compared to 25% in the general population.9
Insulin resistance (IR) has been previously shown to increase the risk of
NAFLD and liver fibrosis.10,11 IR increases hepatic de novo lipogenesis12 and
adipose tissue dysfunction, promoting the release of pro-inflammatory adipokines
and cytokines,13 and leading to chronic hepatic inflammation. IR is likely related
to immune activation, which remains increased in PLWH even after successful
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ART.14 It has been previously shown that PLWH with NAFLD have nearly twice
the likelihood of developing NASH compared to uninfected individuals.15
Among PLWH, ART use has been hypothesized as a major factor in the
development of NAFLD, possibly related to increased IR. Nucleoside reverse
transcriptase inhibitors (NRTIs) have traditionally been considered the most
harmful classification of ART drugs related the development of NAFLD, likely by
increasing IR and dyslipidemia.16-18 Older NRTIs may decrease lipid oxidative
phosphorylation, increase reactive oxygen species (ROS) and lead to an
accumulation of lipids in the liver.19 Newer NRTIs have been shown to have more
favorable impacts on metabolic markers.20-21 Protease inhibitors (PIs) also
appear to be detrimental to metabolic health by increasing hyperglycemia,
hyperinsulinemia and impaired secretion of insulin from beta cells.22-23
Increased microbial translocation may also contribute to NAFLD
development and related inflammatory processes. Visceral adipose tissue (VAT)
and Kupffer cells in the liver respond to activated Toll Like Receptor-4 (TLR-4)
and increase transcription of TNF-a and IL-6, which can both contribute to IR.24,25
In PLWH, individuals who start ART as early as the first 2-3 weeks after HIV
infection continue to have increased levels of plasma markers of microbial
translocation.26 Microbial translocation promotes liver fibrosis through activation
of Kupffer cells and Hepatic Stellate Cells (HSCs).27 Activated HSCs are
associated with higher levels of tissue inhibitor of metalloproteinases (TIMPs).
Increased TIMP promotes liver fibrosis by inhibiting the breakdown of the
extracellular matrix (ECM).28,29
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The progression from NAFLD to NASH is likely facilitated by HSC
activation and proliferation. Increased insulin and glucose, hallmarks of NAFLD
increase HSC activation and connective tissue growth factor (CTGF), both
promoters of liver fibrosis.30 The activation of HSCs is also increased in settings
of liver apoptosis and elevated ROS.31 Increased ROS damages mitochondrial
membranes and ultimately leads diminished mitochondrial function32,33 and
increased hepatic apoptosis.34,35 Furthermore, individuals with NASH have
reduced antioxidant capacity which corresponds to NASH severity.36,37 Apoptosis
related to NASH can be initiated FFA accumulation,38,39 and exposure to
inflammatory cytokines.40,41 Viral HIV envelope proteins contribute to hepatocyte
apoptosis both directly and through inflammatory pathways.42,43
Significance of the Study
Due to the high level of liver disease mortality among PLWH, it is
imperative to understand the interaction between multiple physiological and
lifestyle factors that may lead to liver disease in this population. Poor metabolic
health has been previously associated with greater liver fibrosis development in
PLWH11; however, to the best of our knowledge there are no studies that have
looked directly at the effect of insulin resistance and liver steatosis on immune
activation, liver fibrosis pathways and the likelihood of liver fibrosis in PLWH. This
work fills in important gap in the current research literature and builds upon
previous findings from the MASH Cohort. Previously published literature from the
MASH Cohort has focused on the effect of anti-oxidant nutrients,44 and different
aspects of social and lifestyle including alcohol abuse, cocaine abuse, and food
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insecurity.45-47 As advances in ART continue to increase the quality of life in
PLWH it is vital to focus on the role of metabolic health as a determinant of liver
disease outcomes in the MASH Cohort which is now composed of individuals
with high rates of ART adherence and controlled HIV Viral Load.
Innovation
The TyG Index is a marker of insulin resistance,48 that has been shown to
be associated with steatosis.49 It is calculated from the following equation.
.)
.)
$%&'(") +, - /! 0 ∗ $%&'(") )2345&6 - /! 0
!" #
8
2
Unfortunately, the gold standard for detecting steatosis is liver biopsy or
MRI-PDFF scans, both of which can be invasive, expensive, and not for practical
use among larger populations. The TyG Index only requires values from a much
easier to obtain blood draw that occurs at routine health screenings. Analyses
throughout this work show similar findings between TyG Index and liver steatosis
for biomarker and liver disease outcomes, reflecting the possibly of using the
TyG Index in PLWH as a proxy for steatosis risk. Furthermore, these analyses
were performed in a manner to detect possible cumulative effects from the HIV
virus and steatosis risk, while controlling for cocaine use.
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AIM FOR CHAPTER III: THE TRIGLYCERIDE-GLUCOSE (TYG) INDEX AS A
PREDICTOR OF LIVER STEATOSIS IN THE MIAMI ADULT STUDES ON HIV
(MASH) COHORT
Specific Aim 1: Determine if the TyG Index is a predictor of NAFLD in the MASH
Cohort.
Hypothesis 1a: The TyG Index will be a predictor of liver steatosis in both
uninfected controls and PLWH when controlling for Age, Sex, BMI, Cocaine Use,
and HIV Status.
Hypothesis 1b: The TyG Index will be a better predictor of liver steatosis in
PLWH compared to uninfected controls.
AIM FOR CHAPTER IV: THE TYG INDEX AND LIVER STEATOSIS ARE
ASSOCIATED WITH GREATER LEVELS OF IMMUNE ACTIVATION AND
LIVER FIBROSIS BIOMARKERS IN THE MIAMI ADULT STUDIES ON HIV
(MASH) COHORT
Specific Aim 2: Determine if the TyG Index is an independent predictor of
biomarkers of immune activation and liver fibrosis.
Hypothesis 2a: Higher TyG Index values will be associated with increased
levels of immune activation and liver fibrosis.
Hypothesis 2b: Cocaine use and HIV infection will be significant predictors
of immune activation, and liver fibrosis.
Specific Aim 3: Determine if there is a cumulative effect between HIV infection
and liver steatosis on biomarkers of immune activation and liver fibrosis.

6

Hypothesis 3a: Study groups with HIV infection and liver steatosis will
have higher mean levels of immune activation and liver inflammation biomarkers
compared to uninfected controls and participants without liver steatosis.

AIM FOR CHAPTER V: THE TYG INDEX IS ASSOCIATED WITH GREATER
LIVER STIFFNESS AND LIVER FIBROSIS IN PEOPLE LIVING WITH HIV
(PLWH)
Specific Aim 4: Determine if there is an association between the TyG Index and
oxidative stress, apoptosis and liver fibrosis in the MASH Cohort.
Hypotheses 4a: Higher TyG Index values will be significantly associated
with increased oxidative stress, apoptosis, and liver fibrosis.
Hypothesis 4b: Cocaine use and HIV infection will be significant predictors
of oxidative stress, apoptosis, and liver fibrosis.
Specific Aim 5: Determine if there is a cumulative effect between HIV infection
and liver steatosis on mean levels of oxidative stress, apoptosis, and liver
stiffness.
Hypothesis 5a: Study groups with HIV infection and liver steatosis will
have higher mean levels of oxidative stress, apoptosis, and liver stiffness
compared to uninfected controls and participants without liver steatosis.
Sample Size
This study selected 480 participants (211 PLWH, 269 uninfected controls)
from the Miami Adult Studies in HIV (MASH) Cohort who were recruited to the
FIU-Borinquen Research Clinic for participation in the parent study.
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STATISTICAL ANALYSIS
Table 1. Summary of the primary hypothesis, independent variables, dependent
variables and statistical tests performed for each chapter.
Hypotheses
Primary
Primary
Statistical Analyses
Independent
Dependent
Variables
Variables
Chapter III
TyG Index
Liver Steatosis
T-Test, Chi-Square,
Hypothesis 1a
Multiple Logistic
Regression, ROC Curve,
Youden Index
Chapter III
TyG Index
Liver Steatosis
T-Test, DeLong ROC
Hypothesis 1b
Comparisons Test
Chapter IV
TyG Index
sCD14, sCD27,
T-Test, Pearson
Hypothesis 2a
Correlation, Multiple
sCD163, TGF-b,
Linear Regression
TIMP-1
Chapter IV Cocaine Use, HIV
sCD14, sCD27,
Pearson Correlation,
Hypothesis 2b
Infection
Multiple Linear
sCD163, TGF-b,
Regression
TIMP-1
Chapter IV
HIV Infection,
sCD27, sCD163,
Pairwise Comparisons,
Hypothesis 3a
Liver Steatosis
One-Way ANOVA
TGF-b, TIMP-1
Chapter V
TyG Index
Free GSH,
T-Test, Multiple Linear
Hypothesis 4a
Apoptosis, Liver
Regression
Fibrosis
Chapter V Cocaine Use, HIV
Free GSH,
Pearson Correlation,
Hypothesis 4b
Infection
Apoptosis, Liver
Multiple Linear
Fibrosis
Regression
Chapter V
HIV Infection,
Free GSH,
Pairwise Comparisons,
Hypothesis 5a
Liver Steatosis
Apoptosis, Liver
One-Way ANOVA
Fibrosis
All Multiple linear regression analysis with TyG Index as the primary independent variable will
control for Age, Sex, BMI, Cocaine Use, and HIV status/ HIV VL.
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Chapter II: LITERATURE REVIEW
Direct effects of HIV on NAFLD and Liver Disease Progression
The rate of NAFLD in PLWH is approximately twice as higher when
compared to the general population.1,2 Liver-related disease accounts for
approximately 5.2% of all deaths in PLWH.3 It has been shown that PWLH with
NAFLD have almost double the rates of NASH compared to age/sex-matched
HIV negative controls.4 Lipid accumulation alone increases Hepatic Stellate Cell
(HSC) activation, and this process may be exacerbated by HIV. This was
illustrated by a study that showed that the mean BMI among PLWH with NAFLD
histology was 26 kg/m2, while the mean BMI of non-infected participants with
NAFLD histology was 30 kg/m2. Higher levels of insulin and glucose, hallmarks of
NAFLD, increase HSC proliferation and also increase connective tissue growth
factor (CTGF), another promoter of liver fibrosis.6
The prevalence of liver fibrosis in PLWH ranges between 17-41%.7,8 In
PLWH, the HIV Gp120 protein receptor directly induces apoptosis and instigate
liver injury initiating fibrotic pathways.9 Liver fibrosis is the process of increased
deposition of extracellular matrix (ECM) proteins into the space of Disse, which is
the part of the liver between hepatocytes and liver sinusoids. The cells primarily
involved with the depositing of ECM are HSCs. HSCs must become activated
through release of debris from injured hepatocytes, lipid accumulation, ROS, or
exposure to certain cytokines.10 Over time, increased deposits of ECM and
decline in the removal of these proteins by matrix metalloproteinases (MMPs)
results in a buildup of scar tissue that replaces normal liver parenchyma tissue.11
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NAFLD Prevalence
The prevalence of NAFLD in the general population has been estimated to
be around 20 to 24 %12,13 but may be as high as 50% according to some
studies14,15. The disparities between these ranges may be because this problem
is growing among individuals with chronic liver disease in recent years; the
proportion of liver disease due to NAFLD has increased from 47% to 75% over
the last 20 years.16 This rate is even higher among individuals who are obese
(between 57-98%)12 and have type 2 diabetes.17 Genetically, it appears that
Hispanics present the highest risk of NAFLD development, followed by European
ancestry, then African Americans.18
Mechanisms of Lipid Accumulation in NAFLD
The simplest form of NAFLD is triglyceride accumulation within the liver
that is present without inflammation. When NAFLD is more severe, and is
accompanied by substantial inflammation and possible fibrosis, the condition is
considered NASH. It has been estimated that anywhere from 6-55% of patients
with NAFLD also have NASH.19–21 The development of NAFLD begins with an
increase in insulin resistance (IR), often a consequence of obesity-related
inflammation. In obese individuals, adipocyte expansion leads to adipocyte
dysfunction that results in an abnormal release of adipokines, several of which
are pro-inflammatory.22 This pro-inflammatory state results in IR, which inhibits
the function of the hormone sensitive lipase (HSL), an enzyme which increases
the mobilization of free fatty acids (FFAs) and their transport to the liver.23 Insulin
also increases the synthesis of FFAs in the liver by enhancing the transcription
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factor sterol regulatory element-binding protein-1c (SREBP1-c).24 Along with an
increase in IR, there is an increase in circulating glucose levels. Increased
glucose can also upregulate the synthesis of FFAs in the liver through increased
expression of carbohydrate responsive element-binding protein (ChREBP).24
Dietary factors that can influence the accumulation of FFAs include increased
dietary cholesterol and saturated fat. Both of these nutrients have been shown to
upregulated SREBP-1c, whereas unsaturated fat intake appears to downregulate
SREBP-1c.25 Along with systemic IR, IR can also occur in the liver itself. Liver IR
worsens FFA accumulation and can increase the production of toxic FFA
metabolites such as ceramides. Systemic inflammatory markers such as TNF-a
and IL-6 can also worsen hepatic IR.
Differentiating between NAFLD and NASH
Insulin resistance followed by accumulation of triglyceride in the liver alone
is not a condition that is characterized as NASH. Only when NAFLD is combined
with inflammation and OS is the condition considered NASH. It has been recently
demonstrated that NAFLD and NASH are separate conditions that often occur
simultaneously but can be independent from one another.26 Studies have shown
that NASH development is possible without previous steatosis.27 Hepatocytes
may first become stressed by inflammation or ROS and this may lead to a
downstream accumulation of lipids in the liver. In this case, NASH precedes
steatosis, not vice-versa. NAFLD and NASH typically develop through concurrent
pathways but should be considered separate conditions with a high risk of one of
the conditions preceding the diagnosis of the other.28
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It is important for researchers to fully understand the mechanisms behind
the progression of non-inflammatory NAFLD to inflammatory and possibly fibrotic
and eventually cirrhotic NASH. Increased FFA oxidation, in NASH, appears to
cause substantially more damage than simple triglyceride (TG) accumulation
alone, which is a hallmark of NAFLD. When FFAs are oxidized in the liver toxic
metabolites are formed and can result in OS, inflammation and liver injury.29–31
TG accumulation, common in non-progressive NAFLD, is not toxic when stored
in the liver and it is simply a result of increased FFA transport32 and decreased
removal from beta oxidation, VLDL export, and lipophagy.33,34 Decreased beta
oxidation occurs during early stages of fat accumulation, typically triggered by
increased IR which increases the lipolysis of peripheral fat and increases FFA
transport to the liver.35,36 FFAs from lipolysis make up the majority (59%) of FFAs
present in the livers of NAFLD patients.33 The liver can also contribute to the
buildup of lipids through de novo lipogenesis (DNL) via SREBP1 and ChREBP.37
Each of these transcription factors is further upregulated under conditions of IR.
Insulin also has an inhibitory effect on the CYP2E1 enzyme, the major enzyme
that metabolizes both ethanol and FFAs.38 The CYP2E1 gene expression
positively correlates with liver fat39 and is higher in patients with NASH compared
to simple NAFLD.40,41 This may be due to the production of highly reactive
carbonyl compounds during CYP2E1 FFA oxidation.38,40
Progressing from NASH to Fibrosis
As described above, liver fibrosis is the process of accumulating ECM
proteins in the space of Disse.42 Fibrosis progression is primarily regulated by the
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activation of HSCs and the resulting release of chemical mediators that lead to
deposition of the ECM.43,44 The ECM is regulated by the balance between profibrogenic tissue inhibitors of metalloproteinases (TIMPs) and the anti-fibrogenic
matrix metalloproteinases (MMPs). Levels of TIMPs have been shown to
progressively increase as liver fibrosis advances. The increase in TIMP-1 has
been associated with the activation of HSCs that is the result of increased proinflammatory cytokines that were mentioned above.45 MMPs are a group of zincdependent enzymes that regulate the ECM through inhibition of TIMPs.46 The
upregulation of TIMPs may be a contributor to the development of fibrosis by
inhibiting the breakdown of the matrix.47 The individual pathways outlining the
roles of HIV, OS, apoptosis, and immune activation and inflammation in
pathology of fibrosis are described in their respective sections below.
Role of HIV in Liver Fibrosis
ART blocks uncontrolled viral replication of HIV, but low levels of
replication occur even when ART is considered successful.48,49 The HIV virus
does not replicate inside of hepatocytes, but hepatocytes do have the CXCR4
and CCR5 co-receptors required for HIV binding.50 When HIV activates the
CXCR4 and CCR5 receptors increase pro-collagen alpha-1, one of the
components of type I collagen found in the ECM, a sign of liver fibrosis.51 HIV
can infect HSCs and can directly stimulate collagen I expression and monocyte
chemoattractant protein (MCP-1) in these cells. The HIV envelope protein Gp
120 can also activate TIMP-1.52 The increased expression of TIMP-1 and MCP-1
is heavily involved in the recruitment of leukocytes and fibrosis.
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Oxidative Stress in NASH and Fibrosis
Oxidative stress can be defined as an imbalance between the antioxidant
defenses of the body and the production of reactive oxygen species (ROS). ROS
are oxygen molecules that easily react with and damage biological molecules.
Oxidative stress can be measured via different methodologies to reflect ROS
damage in different tissues in the body. Systemic oxidative stress can be
measured in blood using oxidized glutathione, lipid peroxidation can be
measured by malondialdehyde (MDA) or 4-hydroxy-2-nonenal (HNE), and 7,8dihydroxy-8-oxo-2’-deoxyguanosine (8-oxodG) measures oxidized DNA
damage.53
It has been previously shown that individuals with NASH have higher
levels of OS than those with simple steatosis.54 The most prominent source of
OS is from increased FFA oxidation in the mitochondria.55,56 This primarily occurs
in the electron transport chain at complexes I and II, electrons escape these
complexes and interact with oxygen molecules and form ROS.57 ROS activates
the Jun N-terminal kinase (JNK) pathway that results in mitochondrial damage
within the mitochondrial membrane.58 Mitochondrial damage leaves the electron
transport chain susceptible to further ROS production and the vicious cycle
continues until mitochondrial function is diminished.57,59 Diminished mitochondrial
function decreases ATP production and can also result in cell death linking OS to
apoptosis (see apoptosis section).60,61 OS can also have an effect on DNA
replication; individuals with diagnosed NASH have been shown to have lower
levels of mitochondrial DNA than individuals with simple NAFLD.62 One common
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marker of mitochondrial OS is 8-oxo-dG and this has been shown to be
increased in individuals with NASH.63
In addition to an increase in ROS production in NAFLD and NASH, there
also appears to be a decrease in antioxidant capacity. Increased ROS production
consumes the antioxidant molecules glutathione and coenzyme Q10. Also,
antioxidant enzymes appear to be inhibited by oxidation. Decreased antioxidant
enzyme capacity correlates with severity of NASH.64,65
HIV and Oxidative Stress
The HIV virus induces oxidative stress by several mechanisms; HIV
envelope proteins Gp120, Tat, Nef, Vpr, RT each have connections to oxidative
pathways, but the Gp120 protein likely has the most prominent effect on the liver.
Gp120 binds to the chemokine receptors CCR5 and CXCR4 on the HIV virus.
When Gp120 exposure to these receptors increases, expression of
proinflammatory cytokines including TGF-ß1, MCP-1, IL-6, and TIMP-1 are
increased. TGF-ß1 promotes hepatic fibrosis and the increase in MCP-1 also
results in higher levels of hepatic inflammation and risk for developing fibrosis.46
In addition to promoting pro-fibrogenic pathways through increased
oxidative stress, the HIV virus also decreases antioxidant defense systems.
Studies have shown that the Gp120 and Tat envelope proteins lead to the
downregulation of glutathione synthase (GSS), glutathione reductase (GR) and
glutathione peroxidases (GPx). The result of this down regulation is a decrease
in the total glutathione content and an increase in the oxidized glutathione
(GSSG) to total glutathione (GSH) ratio.66,67 The effect of Tat on reduced
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glutathione production is most likely stronger than the effect of Gp120.66
Furthermore, Vpr is another protein on the surface of the virus that may reduce
GSH levels by decreasing ATP synthesis in mitochondria. Decreased ATP
synthesis reduces the levels of GSH because two molecules of ATP are required
for the synthesis of every glutathione molecule.68,69
Oxidative stress has been shown to facilitate disease progression and
liver disease-related mortality. Increased oxidative stress can lower CD4+ counts
and damage DNA within CD4+ cells.70–72 Also, evidence shows OS may stimulate
HIV replication,73 play a role in in accelerated aging, and contribute to the
development of chronic diseases.74
Two markers of OS that are of particularly relevant to this review are MDA
and HNE. Each of these markers are secondary aldehydes that are formed during
lipid peroxidation and can cause liver damage. HNE is likely the most toxic
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and

significantly correlates with the grade of inflammation and fibrosis.76 HNE adducts
are aldehyde metabolites of lipid peroxidation and have been shown to increase
during NASH progression.
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An important inflammatory pathway in the

progression of NAFLD are the Toll-like receptor (TLR) pathways. Specifically,
TLR-7 is a pathway that may reduce lipid accumulation within hepatocyte and
reduce the risk of NAFLD. Increased levels HNE and MDA seen in HIV
70,71

have been shown to inhibit TLR-7 and worsen NAFLD progression.78 HNE can

also activate the c-Jun NH2-terminal kinase (JNK) pathway, which is a regulator of
metabolic pathways that contribute to NAFLD and liver injury. This supports the
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biomarker of OS.79
Mitochondrial Dysfunction in NASH and Liver Fibrosis
NAFLD develops due to the rate of beta oxidation lagging behind FFA
accumulation from increased FFA uptake and synthesis. The initial decrease in
beta oxidation of FFAs lead to the production of ketone bodies. In the previous
sections it was mentioned that IR increased expression of SREBP-1. SREBP-1c
induces an increase in acetyl-CoA carboxylase-2 (ACC2) which increases
malonyl-CoA and results in decreased expression of carnitine
palmityltransferase-1 (CPT1) inside of the mitochondria. The final result of
decreased CPT1 is decreased beta oxidation of fatty acids and lipid
accumulation.
As lipid accumulation progresses, FFA oxidation begins to increase as a
compensatory mechanism. This is accomplished through increased activity of the
PPAR-alpha gene. This gene enhances the activity of CPT-I and CPT-I loses
affinity for malonyl-CoA,55,80,81 resulting in an increased in FFA beta-oxidation.
Increased oxidation of FFAs however, results in increased ROS production and
possibly toxic metabolites, including oxidized cardiolipin82,83 and ceramides.84
Lastly, increased ROS produced from oxidation of FFAs result in damage to the
electron transport chain of mitochondria directly, and damage to mitochondrial
DNA.59 ROS also results in elevations in mitochondrial Ca2+ which produces
more ROS. Ca2+ increases the delivery of electrons to the electron transport
chain but blocks the protein complex within the chain which increases electron
leakage from the chain and promotes ROS production85 Much of this Ca2+ comes
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from a stressed endoplasmic reticulum (ER).86 Mitochondrial damage from ROS
over time will eventually result in decreased beta oxidation of FFAs, which will
make NAFLD even worse, increase OS and inflammation, and trigger fibrosis
pathways.
HIV and Mitochondrial Dysfunction
HIV itself can deplete mitochondrial DNA in CD8+ cells, B cells, and CD4+
cells. Mitochondrial dysfunction is another factor that can induce apoptosis, lipid
accumulation and eventual fibrosis.87,88 Accumulation of lipids occurs due to a
decrease in beta-oxidation of fatty acids, the lipids accumulate and can lead to
liver fibrosis development60,89 Adipose tissue in PLWH actually has an increase
in mitochondrial content. This could be a compensatory mechanism or simply
alter lipid metabolism and promote liver fat accumulation. Additionally, it has
been previously demonstrated that ART may also induce mitochondrial toxicity
(see ART section below).87,89
Apoptosis, NASH, and Fibrosis
Apoptosis is one of the most distinguishable features that separates
individuals with NASH from NAFLD.90 Greater apoptosis correlates with greater
degree of liver injury in NASH.91 One of the major proposed mechanisms
initiating apoptic pathways is excess lipid accumulation, mainly FFAs. All four
apoptosis pathways, intrinsic, extrinsic, ER stress, and lysosomal, can be
initiated by FFA accumulation.30,84 The intrinsic or mitochondrial pathway is
initiated by cellular stress that results in increased mitochondrial membrane
permeability and release of pro-apoptic proteins into the cytosol .92 The source of
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cellular stress in this pathway is increased mitochondrial OS.93 Dietary saturated
FFAs can activate the pro-apoptic proteins Bax and PUMA via the JNK activation
pathway.94–96 In addition to mitochondrial stress, endoplasmic reticulum (ER)
stress can also activate apoptic pathways from saturated FFAs through JNK
signaling as well.97 This occurs due to disruption of Ca2+ release from the ER.98
Extrinsic apoptosis can be trigged via pro-inflammatory cytokines released
during the inflammatory processes discussed previously. This pathway is initiated
when cell plasma membranes activate their cytokine receptors to proinflammatory cytokine ligands, mainly the TNF-R, and TRAILR and Fas
receptors. These receptors trigger apoptosis through the formation of the death
inducing signaling complex (DISC) and subsequent activation of the caspase-2
mediated pathway that cleaves the BH3-interacting domain death agonist (BID)
protein. BID recruits Bax to the mitochondrial and this event then triggers intrinsic
apoptosis.99,100 It appears that the most important apoptic pathway in NASH are
the Fas/FasL and the TRAILR/TRAIL pathways, likely due to FFAs initiation. Cell
lines treated with these ligands show increased susceptibility to apoptosis.100,101
The lysosomal pathway induces apoptosis by releasing cathepsin B into
the cytosol.102,103 This pathway links to the intrinsic pathway by activating procaspase 2 and inducing increased mitochondrial membrane permeability.104
HIV and Apoptosis
HIV likely induces apoptosis via the death receptor pathway through its
envelope protein Gp120. Gp120 interacts with the chemokine receptors CCR4
and CCR5 on several different types of cells, including hepatocytes and CD4+
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lymphocytes which triggers apoptosis 105 Gp120 induces hepatocyte apoptosis
by increasing the expression of TRAIL receptor.106 Higher HIV VL could lead to
more Gp120 exposure to hepatocytes and therefore leading to greater rates of
apoptosis in inflammation.107
Gp120 within infected hepatocytes leads to apoptosis of those cells;
however, apoptosis can spread to non-infected CD4+ cells and lead to their longterm depletion. HIV infected cells may induce apoptosis in non-infected CD4+
cells by a process called “bystander killing”.108 This can be accomplished in
multiple ways. The infected cell and a healthy CD4+ cell may partially fuse and
produce an interaction between HIV viral proteins and receptors on the
noninfected cell and exchange lipid membranes. This partial fusion and
interaction triggers cell death in the uninfected cell.109 Infected cells can also go
through the process of complete cellular and nuclear fusion which will eventually
lead to cell death of the fused cell later on in the cell cycle.110 Lastly, when
infected cells begin going through the process of apoptosis, they can fuse with
noninfected CD4+ cells and apoptosis is induced in both cells.111
Microbial Translocation and Inflammation in NASH
Common markers of increased microbial translocation are LPS, LPS
binding protein, and sCD14. sCD14 has been shown to be increased in PLWH
and correlated with liver fibrosis. LPS activates toll-like receptor 4 (TLR-4), TLR-4
actives Kupffer cells in the liver which produce pro-inflammatory cytokines that
can activate HSCs or recruit other immune cells.112,113 Kupffer cells play a major
role in the overall inflammatory response in the liver and attempt to repair liver
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damage.114 HIV may deplete Kupffer cells which may reduce HSC activation, but
overall inflammatory effect remains due a decreased ability to clear microbial
translocation products from the liver.115,116 Kupffer cells have been shown to
release TGF-b in response to TLR-4 from LPS indicating a direct fibrotic
response.117 In addition to the activation of Kupffer cells and HSCs, LPS can also
promote hepatocyte cell death through the systemic immune response and
increased production of proinflammatory cytokines.118,119 Increased microbial
translocation products as a result of dysbiosis or gut endothelial damage may
also contribute to NAFLD development. The primary microbial translocation
product of concern is LPS, which activates TLR-4 and can enhance the
production of ceramide synthesis, a toxic metabolite. Visceral adipose tissue and
Kupffer cells respond to TLR-4 with increased production of TNF-a and IL-6
which can both contribute to IR.120,121 Inflammation in NASH can be traced back
to inflammatory cytokines from adipose tissue, the gut, or the liver itself.122
Obesity leads to increased adipocyte size that results in dysregulation of
adipocytes which Dysregulated adipocytes increase the production of proinflammatory cytokines that results in IR.123,124 Obesity activates macrophages in
adipose tissue to switch to a pro-inflammatory M1 state that can also contribute
to inflammatory cytokine production.125
FFAs are recognized as danger-associated molecular patterns in the liver
(DAMPs). DAMPs can activate the NALP3 inflammasome that activates procaspase-1 and increases pro-inflammatory cytokine production.126 DAMPs can
also derive from dying hepatocytes and activate inflammatory pathways through

26

TLR. FFAs also enhance expression of TNF-a through the NF-kB pathway.102 In
addition to TNF-a, NF-kB also upregulates TGF-B, IL-6, and IL-8, which are all
primary promoters of apoptosis and fibrogenesis driving the progression of
NAFLD to NASH.127
HIV and Microbial Translocation
Previous studies have found reduced integrity of the gut mucosa lower in
PLWH due to damage of enterocytes.128 Enterocyte damage allows microbial
products typically found in the GI tract, mainly lipopolysaccharide (LPS), to leak
from the intestine and travel to the liver via the portal vein.128 The disruption of
the mucosal layer is likely due to a depletion of CD4+ and CD22 cells in the
intestine.129–132 Higher levels of LPS in circulation increase production of
inflammatory cytokines by gut enterocytes leads to epithelial apoptosis.
Increased endothelial apoptosis is associated with the disruption tight junctions
between enterocytes and loss of gut integrity which further perpetuates higher
levels of LPS in circulation. 130,132,133
ART and Metabolic Health
One of the main concerns in the development of NAFLD among PLWH is
the detrimental effect of ART on blood lipids. The most harmful classification of
ART drugs related to the development of NAFLD are nucleoside reverse
transcriptase inhibitors (NRTIs). Older NRTI drugs were associated with insulin
resistance and dyslipidemia, likely due to mitochondrial toxicity from the
drugs.134–136 These drugs can impair mitochondrial DNA replication which results
in decreased oxidative phosphorylation of lipids, increased ROS, and an
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accumulation of liver fat.137 Early generation NRTIs that had the worst impact on
metabolic outcomes were stavudine, didanosine, and zalcitabine. Modern NRTIs
with much more favorable impacts on metabolic outcomes include tenofovir,
abacavir, lamivudine, and emtricitabine.138,139 Protease inhibitors (PIs) are the
second classification of ART drug with strong links to poor metabolic health. It
appears the main mechanism that PIs acts as a detriment to metabolic health is
through insulin resistance. PIs have been associated with hyperglycemia,
hyperinsulinemia, and impaired secretion of insulin from beta cells.140,141 Older
PIs with the worst effects on insulin resistance are indinavir and ritonavir.142
Current protease inhibitors atazanavir and darunavir have more favorable profiles
metabolic profiles.143 Protease inhibitors may increase adipocyte size due to
inhibition of GLUT-4 activity.144 Enlarged adipocytes are insulin resistant and
these cells secrete less adiponectin, which increases body fat worsening liver fat
and fibrosis.145
HIV and Nutrition
The role of nutrition in PLWH has changed drastically over the last few
decades. When the HIV virus was first identified, one of the most distinguishable
features of the disease was the muscle wasting that was very visible in
individuals who were in advanced stages of the disease. However, advances in
ART have completely changed the nutritional outlook for the majority of PLWH,
instead of eating to avoid muscle wasting these individuals are managing
obesity, elevated blood lipids, and type two diabetes (T2DM).146,147 Therefore, for
PLWH one of the most important considerations to their dietary
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recommendations are their HIV viral load (VL), ART use and adherence, and
their current BMI. Individuals who present classic symptoms of muscle wasting
such as low BMI or recent decrease in BMI will be treated very differently than
those who have a well-controlled disease and have a healthy or high BMI.
Areas of focus for individuals displaying signs of muscle wasting include
reversing weight loss and a decrease in muscle mass, fluid accumulation, and
correcting insufficient energy intake.148 PLWH who appear to be more at risk for
over-nutrition should focus on blood lipids, insulin and glucose, and blood
pressure. Nutrition related health concerns that all PLWH should pay close
attention to include iron and B12 related anemia,149 gut health, diarrhea and bone
density.150,151 The focus of this review will remain on the role of nutrition in the
development of NAFLD and NASH in PLWH.
Additionally, because HIV is an immune deficiency virus, the immune
system needs optimal nutrition support. It has been previously shown that B
vitamins and the antioxidant vitamins C and E influence the function of the
immune system.152 Often in PLWH micronutrient deficiencies can precede HIV
disease progression.153, 154 Supplementation of micronutrients in PLWH has
reduced the risk immunological decline HIV morbidity.155 Also zinc intake has
also been associated with immune function in this population and may promote a
health gut mucosa and reduce diarrhea.156 Zinc also works as an antioxidant in
the body and is associated with OS when deficient.157 Through this pathway zinc
has been shown to be associated with liver fibrosis progression.158 Optimal zinc
intake is important in PLWH due to over 50% of the PLWH population having low
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zinc concentrations.153,159,160
Dietary Factors in the Development of NAFLD and NASH in PLWH
As discussed above, the initial factor that typically initiates the cascade of
events that lead to lipid accumulation in the liver is obesity. Obesity in turn
increases susceptibility to inflammation and insulin resistance resulting in liver fat
accumulation. Current recommendations for individuals with NAFLD, whether or
not they are living with HIV, begins with weight loss. The current weight loss
recommendation to reduce liver fat is 5-10% of body weight.161 Weight loss in
PLWH is complicated and should be aided with outpatient nutritional counseling.
Patients should plan on making long-term changes and not short-term weightloss goals.162 Weight loss interventions should include the entire healthcare team
including social workers and community service organizations that may help with
potential food insecurity issues.
Cholesterol from the diet can induce SREBP-1c activation through the
liver X receptor (LXR) transcription factor. LXR also activates ChREBP, stearoylCoA desaturate, and FFA synthase. Saturated fatty acids may also modulate
SREBP-1c activation. It has been shown that dietary saturated fatty acids can
upregulate the SREBP-1c gene and unsaturated fatty acids downregulate this
gene.25 Fructose intake also activates both SREBP-1c and ChREBP as well.
SREBP-1c is activated through the buildup of advanced glycation end products
associated with chronic fructose intake and ChREBP is activated through
fructose intermediate products and activation of glycogen kinase (GK).163,164
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Diet and Microbial Translocation

It is known that the microbiome plays a major role in microbial
translocation and dietary composition is heavily involved. A Western style diet
made of high fat and high sugar content along with low fiber intake is associated
with the development of obesity.165 This type of diet has been previously
associated with reduced microbial diversity in the gut.165 This link may be related
to the development of NAFLD through the gut-liver axis.166,167 A healthy and
diverse gut microbiome produces beneficial compounds such as short-chain fatty
acids (SCFAs) whereas dietary components of a Western diet such as fructose,
saturated fat, and cholesterol may alter the microbiome in a manner that allows
increased gut permeability and translocation of harmful microbial compounds to
the liver via the portal vein.168 In PLWH, the HIV virus itself causes damage to
the gut mucosa layer and exacerbates the translocation of microbial products to
the portal circulation. The result of increased microbial translocation due to
dietary or viral factors results in increased LPS transport, immune cell activation
and inflammation through the TLR-4 pathway occurs as discussed in above
sections. One of the major consequences of the TLR-4 pathway activation is an
increase in OS that can result in greater hepatocyte apoptosis and activation of
the NF-kB pathway. Additionally, saturated FFAs activate or amplify signaling
through TLR4 in a synergistic manner with LPS.169 Dietary components related to
downregulation of OS and inflammation include intake of antioxidant
micronutrients and polyunsaturated fatty acids (PUFAs).
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Dietary and microbial factors within the gut also play a major role in the

development of hepatic inflammation.170 Specific nutritional components that are
thought to be contributors include saturated fat and fructose; these components
increase intestinal permeability to gut microbial products such as LPS.171
Fructose can increase the presence of certain bacterial species in the gut that
promote bacterial overgrowth and increase LPS.168,172 Gut barrier dysfunction in
patients with NAFLD has been previously demonstrated and led to increased
LPS leakage through the intestinal membrane.171,173 Through this pathway high
fructose intake is able to activate Kupffer cells and HSCs in the liver and initiate
pro-inflammatory and fibrotic pathways.174–176
Substance Abuse, NAFLD and NASH
Among individuals enrolled in HIV care, the prevalence of substance
abuse disorders (SUD) is estimated to be approximately 48% overall. This rate
varies from 21 to 71% depending on the specific site.177 It is important to identify
these individuals because SUDs have been shown to delay ART treatment and
are individuals using them are less adherent to their medications. 178–180 In
addition to negatively affecting their HIV treatment, different substances of abuse
my directly impact HIV disease progression.156,181,182 When multiple substances
of abuse are combined, such as in the case of alcohol and cocaine, the risk of
virologic failure is greatly increased.178
For this review, three substances of abuse will be discussed: alcohol,
cocaine, and opioid use. Over 60% of PLWH use alcohol and about 15% have
reported binge drinking within the last 30 days.183 Previous studies have shown
quicker liver disease progression among heavy alcohol drinkers than individuals
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with NAFLD.184 ALD has been shown to increase liver-related mortality more so
than simple steatosis.185
The prevalence of cocaine use disorder among those in HIV care in one
study was shown to be 11% and 50% in a separate cohort.177,182 Cocaine use
has been shown to greatly reduce ART adherence and ability to suppress VL.178
Cocaine usage has also been shown to have a negative biological impact on
PLWH as well. Cocaine use has been shown to increase HIV transcription and
replication.186 This leads to accelerated HIV disease progression as measured by
reduced CD4+ cell count and increased mortality.182,187 Cocaine use has also
been shown to have an effect on the development of fatty liver. As discussed
earlier, protease inhibitor usage has been shown to be an independent risk factor
increased hepatic triglyceride content.188 Interestingly, in participants who had
never used cocaine, there was no association between duration of PI use and
hepatic triglycerides. However, when participants had used cocaine, this
relationship was significant. The authors hypothesized that cocaine use may
exaggerate the toxicity pathways that define the relationship between PIs and
steatosis development.188
Summary
PLWH are much more likely to develop liver disease than individuals
without HIV. This population presents unique challenges to the liver in the form of
increased microbial translocation, inflammation, and oxidative stress.
Additionally, PLWH are more prone to potentially damaging behaviors such as
drug and alcohol abuse than advance liver disease. It is imperative to study how
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HIV, metabolic disease, and substance abuse interactions may affect the
development of liver disease. Identifying predictors of liver disease in this
population through dietary habits, substance use habits, biological biomarkers, or
MRE technology can provide insight for health care providers to optimize their
care of PLWH and reduce their risk of developing liver disease.
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CHAPTER III: THE TRIGLYCERIDE-GLUCOSE (TYG) INDEX AS A
PREDICTOR OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN THE
MIAMI ADULT STUDIES ON HIV (MASH) COHORT
Introduction
The prevalence of Non-alcoholic fatty liver disease (NAFLD) in the general
population has been estimated to be around 20-24%,1,2 but some studies have
estimated it to be as high as 50% of the population.3,4 People living with HIV
(PLWH) have been previously shown to have higher rates NAFLD compared to
the general population.5,6 The contribution of NAFLD to overall liver disease has
increased over the past 20 years from 47-75%.7 Among obese individuals, the
contribution of NAFLD to overall liver disease is even higher, representing
between 57-98% total liver disease cases.2 Individuals of Hispanic ethnicity
represent the highest risk of developing NAFLD, followed by whites of European
ancestry and it appears Black individuals have the lowest risk of NAFLD
development.8
The development of NAFLD is thought to be a result of increased insulin
resistance (IR),9 which results most commonly from obesity-related inflammation.
A pro-inflammatory state can inhibit the function of hormone sensitive lipase
(HSL), thus increasing the mobilization of free fatty acids (FFAs) in the blood
steam resulting in their transport to the liver.10 Furthermore, insulin increases the
synthesis of FFAs in the liver by increasing the transcription of sterol regulatory
element-binding protein-1c (SREBP1-c).11 Secondary to an increase in IR, is a
subsequent increase in blood glucose concentrations. Increased blood glucose
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upregulates carbohydrate responsive element-binding protein (ChREBP) which
also increases FFA synthesis in the liver. Dietary factors also appear to play a
role in the regulation of SREBP1-c. Cholesterol and saturated fat have both been
associated with upregulation of SREBP-1c.12
Among PLWH, antiretroviral therapy (ART) use has been a major factor in
the development of NAFLD, possibly related to increased IR. Nucleoside reverse
transcriptase inhibitors (NRTIs) have traditionally been considered the most
harmful classification of ART drugs related to the development of NAFLD. Older
NRTIs were associated with increased IR and dyslipidemia.13-15 NRTIs have
been previously shown to decrease lipid oxidative phosphorylation, increase
reactive oxygen species (ROS) and lead to an accumulation of lipids in the
liver.16 Newer NRTIs have been shown to have more favorable impacts on
metabolic markers.17-18 Protease inhibitors (PIs) also appear to be detrimental to
metabolic health through the development of IR. PIs have been associated with
hyperglycemia, hyperinsulinemia and impaired secretion of insulin from beta
cells.19-20 Additionally, PIs may increase adipocyte size due to having an
inhibitory effect on glucose transport-4 (GLUT-4).21 Enlarged adipocytes have
been shown to release less adiponectin, worsening liver fat accumulation.22
Further complicating the relationship between HIV and metabolic health is
cocaine use. The prevalence of cocaine use disorder among PLWH has been
estimated between 11-50%.23,24 Cocaine has been shown to reduce ART
adherence and decrease the number of PLWH maintaining a suppressed viral
load.25 Uncontrolled viral load leads to accelerated HIV disease progression and
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increased mortality.23,26 Additionally, HIV VL has been shown to be inversely
correlated with BMI in men, explaining one possible mechanism behind reduced
bodyweight among PLWH who abuse cocaine.27
Combined, multiple stressors including: HIV infection, ART toxicity, insulin
resistance, and cocaine use, foster an environment that increases the risk of
developing liver disease in PLWH. Due to the difficulty in measuring liver fat in
large populations using Magnetic Resonance Imaging – Protein Density Fat
Fraction (MRI-PDFF) or liver biopsy, identifying an easier to obtain measure that
correlates well with liver steatosis can be a valuable asset in studying liver
disease risk in the PLWH population going forward. The triglyceride-glucose
index (TyG Index) is a measure of metabolic health that has recently been used
as an indicator of IR.28 The TyG index has been shown to be a superior predictor
of NAFLD than the homeostatic model for insulin resistance (HOMA-IR).29 The
TyG Index is composed of fasting triglycerides and blood glucose, both of which
are easily obtain using a fasted blood draw and make up two of the five
components of metabolic syndrome. Insulin resistance has previously been
shown to be a predictor of NAFLD in the general population,30 but IR was not
measured via the TyG index and the study population did not include PLWH.
Cross-sectional studies have previously found associations between the TyG
Index and NAFLD,31 but not in a population of PLWH. The purpose of this paper
is to determine if the TyG Index is a valid marker of liver steatosis or NAFLD, in
PLWH and to determine the effect of HIV infection and cocaine use on liver
steatosis risk.
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Methods:
Study Participants: All participants for this cross-sectional study were enrolled in
the Miami-Adult Studies in HIV (MASH) cohort. The MASH cohort is a
longitudinal study cohort with the primary focus of determining the effect of HIV,
Hepatitis-C Virus (HCV), HIV/HCV and common co-morbidities associated with
these infections on liver disease progression. Inclusion criteria for the current
study include HIV monoinfection, referred to as PLWH, or the absence of HIV
and HCV infection (uninfected controls). Individuals with HCV were not included
in these analyses. To be considered a cocaine user for this study participants
had to have either stated they were cocaine users in a drug screening
questionnaire, blood metabolite testing or urine toxicology screen (American Bio
Medical, Kinderhook, NY). Alcohol use was assessed by the Alcohol Use
Disorders Identification Test (AUDIT).32 For analyses of the PLWH only group,
only individuals who reported using ART within the last 6 months were included.
All participants were required to complete an MRI scan to assess liver steatosis
to be included in final analysis. After exclusion criteria were applied there were a
total of 480 participants included in analysis for this study, 211 PLWH, and 269
uninfected controls. All methodologies were approved by the Institutional Review
Board (IRB) # IRB-20-0273 at Florida International University.

Metabolic syndrome criteria. The criteria used to determine metabolic syndrome
are the same criteria established by the National Cholesterol Education Program-

56

Adult Treatment Panel III (NCEP-ATP III) cohort.33 The NCEP-ATP criteria were
used to categorize participants dichotomous metabolic syndrome status. The
NCEP ATP III defines metabolic syndrome as three or more of the following risk
factors: waist circumference (WC) > 40 inches for men or 35 inches for women,
blood pressure over 130/85 mmHg, fasting triglycerides (TG) > 150 mg/dl, fasting
HDL cholesterol <40 mg/dl in men or <50 mg/dl in women, and fasting blood
glucose >100 mg/dl.

HIV Variables: In participants with HIV monoinfection, HIV Viral Load (VL) and
CD4+ T Cell counts were obtained from the participants’ charts with written
permission. ART use was self-reported over the past six months.

Insulin resistance was measured via the TyG Index using the equation below.28
Both fasting triglycerides and fasting glucose are obtained from the blood draw
from the research nurse and sent to Laboratory Corporation of America as
described in the section above.
.)
.)
$%&'(") +, - /! 0 ∗ $%&'(") )2345&6 - /! 0
!" #
8
2

Dietary Assessment: Each participant completed a 24-hour food recall
administered to them by a trained research assistant. Food items were entered
into the NutriBase nutrient analysis software. Dietary recalls were analyzed for
total calories, total fat, saturated fat, and total cholesterol intake.
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Liver steatosis: Liver fat % is calculated using the proton density fat fraction
(PDFF) score from the magnetic resonance elastography (MRE) scan. Each
MRE scan is performed by a trained technician on participants who are deemed
eligible after a standardized MRE pre-screening questionnaire. PDFF is
converted to liver fat % with the following calculation.34 Participants were
categorized into the liver steatosis group if they had >5% liver fat.34
[100 ∗ (>%' '5 ?%'6@ A%'(5]
[1 + (>%' '5 ?%'6@ A%'(5)]
Statistical Analyses
Descriptive statistics including mean and standard deviation were used to
describe participant characteristics. Differences between the PLWH and
uninfected control groups were detected using independent t-tests and chisquare tests. HIV VL was not normally distributed and was Log10 transformed to
bring distribution closer to normalization. Chi-square analysis was used to
compare the odds of meeting metabolic syndrome criteria between study groups
as well as to compare odds of meeting metabolic syndrome criteria when
participants were separated by liver steatosis status. Unadjusted logistic
regression analysis was used to compare the relationship between all relevant
demographic variables and covariates with liver steatosis risk. Multivariate
logistic regression was performed to combine relevant demographic variables
and covariates in a single model to assess whether the relationships between
variables of interest, TyG Index and HIV status, were independent of one
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another. All covariates included in multivariate regression analysis were included
based on previous relevant literature. An ANCOVA was performed to determine
the estimated TyG Index mean when participants were divided by liver steatosis
status while HIV status and cocaine use were controlled for as covariates. A
receiver-operator curve (ROC) analysis was performed to determine the
predictive ability of the TyG Index on the outcome of liver steatosis in different
study groups. Comparison of ROC Curves between PLWH only and the
Uninfected Control group were performed using the DeLong test in XL Stat.35

Results
Participant characteristics: There were 480 total participants included in
analysis for this study, 211 PLWH and 269 uninfected controls. The control group
was older than the PLWH group (54.85 years ± 7.13 vs. 53.18 ± 7.57, P=0.014).
The uninfected control group also had a lower BMI than the PLWH group (30.05
kg/m2 ± 6.37 vs. 28.74 ± 6.05, P=0.022). There were no differences between
study groups in terms of sex or race. Only one ATP-III metabolic syndrome
criteria were different between study groups. Waist circumference was higher in
the control group 38.54 in. ± 6.14 compared to the PLWH group 37.42 ± 5.53,
P=0.044. The prevalence of liver steatosis and cocaine use was also not different
between study groups.
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HIV and metabolic syndrome: Table 2 shows the prevalence of each of
the five ATP-III metabolic syndrome criteria by study group. There were no
differences between study groups for any of the five metabolic syndrome criteria
or for the prevalence of metabolic syndrome overall.
Liver Steatosis and Metabolic Syndrome: Table 3 describes the close
relationship between liver steatosis and metabolic syndrome. Individuals with
liver steatosis are more likely to meet the ATP-III criteria for metabolic syndrome
in four of the five criteria. The only metabolic syndrome criteria not associated
with liver steatosis was high blood pressure.
Dietary Intake Pearson Correlations: Table 4. Pearson correlation analysis
found no association between the TyG Index or Liver Fat% and any of the four
dietary variables studied (Total Calories, Total Fat, Saturated Fat, and Total
Cholesterol).
Unadjusted Associations with liver steatosis: Table 5. Unadjusted
regression analysis found age, sex, and race/ethnicity were all demographic
factors not significantly associated with liver steatosis. Greater BMI [OR= 1.118
(1.075-1.164, P<0.001)] and increased TyG Index [OR= 3.065 (2.130-4.409,
P<0.001)] were both strongly associated with greater odds of liver steatosis.
Higher Log10 HIV VL was marginally significant associated with lower odds of
liver steatosis [OR= 0.718 (0.500-1.030), P=0.072], but this relationship did not
reach statistical significance. There was no association between CD4

+

count and

liver steatosis. Cocaine use was associated with a decreased likelihood of having
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metabolic syndrome, the prevalence of metabolic syndrome was 12.8% among

cocaine users and 20.7% among non-cocaine users respectively (P=0.027).
Multivariate Regression Analyses: Table 5. A one unit increase in the TyG
index was independently associated with greater likelihood of liver steatosis
[OR= 2.869 (1.960-4.200), P<0.001]. Higher BMI was also associated with
greater odds of liver steatosis [1.104 (1.056-1.155), P<0.001]. There was no
association between HIV status and liver steatosis.
ANCOVA: Table 6. The estimated mean TyG Index value of the liver
steatosis group was 0.517 units higher (8.949 ± 0.068 vs. 8.432 ± 0.031,
P<0.001) compared to the non-steatosis group when controlling for cocaine and
HIV status.
ROC Analysis: Table 7. When the PLWH group and uninfected control
groups were combined in a single analysis, the AUC=0.712 ± 0.031. The AUC of
the PLWH group was a marginally better predictor of liver steatosis than the AUC
of the uninfected control group (0.738 ± 0.049 vs. 0.702 ± 0.401, P=0.068) (Table
9). The optimal predictive cut-off value for TyG Index to predict liver steatosis in
the PLWH group was 8.5938. In PLWH, chi-square analysis found individuals
with TyG Index values >8.5938 (High Risk) were more likely to have liver
steatosis [4.638 (2.075, 10.368), P<0.001] than participants with TyG Index
values <8.5938 (Low Risk) (Table 10).

Discussion
The key finding in these analyses was the TyG Index was a moderately
good predictor of liver steatosis in the MASH Cohort. This study was able to
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establish an optimum TyG Index cutoff value as 8.5938 in PLWH with a
sensitivity of 0.697 and a specificity of 0.669 to predict liver steatosis. In PLWH,
individuals with a TyG score > 8.5938 were more than 4x more likely to have liver
steatosis compared to individuals with a TyG score <8.5938. The optimal TyG
Index cut-off value in the current study was higher than found by Sterling et al.
2021, who found the optimum cut-off value to predict liver steatosis in a cohort of
HBV and HBV-HIV coinfected participants was 8.38. In the current study, the
total AUC of uninfected controls (0.702) and among PLWH (0.738) were similar
to values found by Sterling et al. among HBV only participants (0.70) and HBVHIV coinfected participants (0.76).36
When controlling for cocaine use and HIV infection, the estimated mean
TyG Index of participants with liver steatosis was 0.517 higher than participants
without liver steatosis. This difference is not as large as was found by Fedchuk et
al. 2014, which found a TyG Index value of 8.8 among participants with mild
steatosis compared to 8.0 among participants without steatosis present.
However, this study had participants with a much greater prevalence of liver
steatosis compared to the current study.37
The development of NAFLD is closely linked to IR and it has been
previously shown that the TyG Index may be a better predictor of NAFLD than
the traditional biomarker HOMA-IR.29 However, to the best of our knowledge, the
TyG Index has not been studied in an HIV monoinfected population, or compared
an uninfected control group to an HIV monoinfected population. A previous
review of NAFLD and HIV identified insulin resistance as a major risk factor for
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NAFLD development in PLWH.38 Interestingly in the current study, HIV infection
was not associated with an increased likelihood of liver steatosis in univariate or
multivariate models. This may be due to a number of factors including: age, waist
circumference, BMI, and improvements in ART technology. The PLWH group
was younger than the uninfected control group, had a lower BMI, and had
smaller mean waist circumference, each of these factors is likely to decrease the
number of participants with liver steatosis.39,40 Additionally, the overall low rate of
liver steatosis in this study population likely made it more difficult to find
statistically significant differences between study groups. The current study
population was found to have a steatosis prevalence of 17.5%, lower than the
majority of studies reviewed by Soti et al.38 This low steatosis rate is despite all
participants in the PLWH group self-reporting ART use in the past 6 months. The
effect of ART on NAFLD remains controversial, Crum-Cianflone et al. 2009 found
no association between ART and NAFLD,40 while more recently Vuille-Lessard et
al. 2016 found PI use was associated with liver fibrosis, but not NAFLD.41 In the
current study, only participants with self-reported ART adherence were included
in the PLWH group analysis, because this group did not have a greater
prevalence of NAFLD than uninfected controls, it does not appear ART increased
steatosis risk, even though the effect of ART was not directly assessed.
A major difference between this study population compared to most other
HIV cohorts studying NAFLD is the racial makeup of the MASH Cohort. The
MASH cohort enrolls a predominately Black population (62.1%), and previous
studies have found lower rates of liver steatosis among Black participants
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compared to Hispanic populations.8 In the current study, it appeared as though
Hispanic ethnicity may be associated with increased risk of liver steatosis
compared to Black participants, (21.8% vs. 16.4%), however the sample size in
the current study was not large enough to detect a statistically significant
difference.
In univariate analysis, cocaine use was associated with lower odds of
having liver steatosis among the entire study population [0.563 (0.339-0.936),
P=0.027]; however, in multivariate analysis cocaine use was no longer
associated with a decreased odds of liver steatosis. Previous research on
cocaine and BMI is conflicting. Soni et al. found no association between cocaine
use and obesity prevalence and Escobar et al. found no association between
severity of crack-cocaine use and BMI.42,43 However, past reviews have
described increased rates of anorexia, malnutrition and weight loss among
cocaine users.44 Further investigation into the effect of cocaine on insulin
resistance in PLWH is needed.
There were no associations between any TyG Index or liver fat% and total
calories, saturated fat, total fat, or total cholesterol intake. There was no
association between total calorie intake and BMI (data not shown). The lack of
any dietary associations is likely more related to each participants ability to recall
their dietary intake and less associated with actual dietary intake. Further studies
looking more directly at the relationship between dietary intake, liver fat and
insulin resistance in PLWH should be pursued.
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Conclusion
The TyG Index appears to be a moderately good predictor of liver
steatosis among PLWH and in the uninfected control group. It also appears the
TyG index may be a slightly netter predictor of steatosis among PLWH. This may
be due to PLWH being exposed to multiple stressors to their liver that increase
the likelihood of metabolic dysfunction and may lead to increased likelihood of
steatosis. Furthermore, it does not appear as though HIV infection or cocaine use
are independent risk factors for NAFLD. Future studies should look to investigate
the relationship between high metabolic risk and TyG Index on the likelihood of
developing liver steatosis, fibrosis, and other comorbidities over time.
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Table1. Participant Characteristics
Participants
Total
N= 480
Age(years)
54.12 ± 7.367

PLWH
(N=211)
53.18 ± 7.574

Uninfected
Controls (N=269)
54.85 ± 7.129

P-Value

46.3%F
53.8%M

43.6%F
56.4%M

48.3%
51.7%

0.303

62.1%
7.9%
29.6%
0.4%

66.4%
7.1%
25.6%
-----

58.7%
8.6%
32.7%
----

0.088
0.562
0.090
----

29.47 ± 6.26
8.52 ± 0.654

28.74 ± 6.05
8.585 ± 0.684

30.05 ± 6.37
8.475 ± 0.628

0.022
0.069

Liver Steatosis
Prevalence

84/480
17.5%

32/211
15.2%

52/269
19.3%

0.233

Cocaine Use
Prevalence

195/580
40.6%

78/211
37.0%

117/269
43.5%

0.148

AUDIT Score

5.05 ± 6.59

4.60 ± 6.21

5.40 ± 6.87

0.185

109/480
22.7%

44/211
20.9%

65/269
24.2%

0.390

Sex
Race
Black (non-Hispanic)
White (Non-Hispanic)
Hispanic
Other
BMI (kg/m2)
TyG Index

AUDIT >8
Log10 HIV VL
Controlled HIV VL
(<200 copies/ml)

0.014

0. 759 ± 1.315
88.8%

603.79 ± 382.93
CD4+ (cells/µL)
Obesity (BMI >30)
42.1%
39.3%
44.2%
0.280
Waist Circumference
38.06 ± 5.906
37.42 ± 5.528
38.54 ± 6.139
0.044
(In)
Glucose (mg/dL)
98.11 ± 46.96
99.53 ± 55.31
97.00 ± 39.23
0.559
Triglycerides (mg/dL)
127.2 ± 89.00
133.67 ± 90.71
122.1 ± 87.47
0.159
SBP (mmHg)
130.2 ± 20.58
128.5 ± 19.91
131.5 ± 21.05
0.122
DBP (mmHg)
81.91 ± 12.80
81.86 ± 12.86
81.94 ± 12.77
0.942
HDL (mg/dL)
58.21 ± 18.76
57.30 ± 18.58
58.93 ± 18.90
0.345
Bold P-Values indicate statistical significance (P<0.05). Data for continuous variables is
presented as mean ± STD. Statistical differences between study groups was detected using
independent t-tests for continuous variables and Chi-Square tests for categorical variables. BMI:
Body Mass Index, TyG Index: Triglyceride-Glucose Index, AUDIT: Alcohol Use Disorders
Identification Tests, HIV VL: HIV Viral Load, SBP: systolic blood pressure, DBP: diastolic blood
pressure, HDL: high-density lipoprotein.
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Table 2. Chi-Square analysis comparing the likelihood of meeting metabolic syndrome
criteria between PLWH and Uninfected Controls
Control
Group
56/268
20.9%

ChiSquare
0.538

P-Value

OR (95% CI)

50/211
23.7%

0.464

1.176
(0.763-1.183)

Low HDL
<40 mg/dL men, <50
mg/dL women

57/269
21.2%

47/211
22.3%

0.082

0.775

1.066
(0.689-1.650)

High BP
≥130 mmHg SBP
or ≥ 85 mmHg DBP

151/269
56.1%

116/211
55.0%

0.064

0.853

0.954
(0.664-1.371)

High TRG
≥ 150 mg/dL

57/269
21.1%

56/210
26.7%

1.963

0.161

1.352
(0.886-2.065)

High WC
≥40 inches men
≥35 inches women

209/266
78.6%

151/198
76.3%

0.348

0.555

0.876
(0.565-1.359)

ATP-III Met S
≥ 3 Met S Criteria

79/265
29.8%

62/197
31.5%

0.147

0.701

1.081
(0.725-1.612)

High Glucose
≥100 mg/dL

PLWH

Bold P-Values indicate statistical significance (P<0.05).
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Table 3. Chi-square analysis describing the relationship between liver steatosis and
each of the five ATP-III metabolic syndrome criteria
No Liver
Steatosis
70/395
17.7%

Liver Steatosis
Present
36/84
42.9%

ChiSquare
25.397

P-Value

OR (95% CI)

<0.001

3.482
(2.105-5.761)

Low HDL
<40 mg/dL men, <50
mg/dL women

76/396
19.2%

28/84
3.3%

8.165

0.004

2.105
(1.254-3.534)

High BP
≥130 mmHg SBP
or ≥ 85 mmHg DBP

217/396
54.8%

50/84
59.5%

0.627

0.428

1.213
(0.752-1.957)

High TRG
≥ 150 mg/dL

77/395
19.5%

36/84
42.9%

20.976

<0.001

3.097
(1.881-5.100)

High WC
≥40 inches men
≥35 inches women

280/380
73.7%

80/84
95.2%

18.378

<0.001

7.143
(2.551-20.004)

ATP-III Met S
≥ 3 Met S Criteria

91/378
24.1%

50/84
59.5%

40.730

<0.001

4.638
(2.826-7.612)

High Glucose
≥100 mg/dL

Bold P-Values indicate statistical significance (P<0.05).

Table 4. Pearson Correlation between TyG Index and Dietary Intake Variables
Total Calories
Saturated Fat
Total Fat (g)
Total
(g)
Cholesterol
(mg)
TyG Index
-0.051
-0.032
-0.012
0.041
P=0.483
P=0.657
P=0.868
P=0.575
Liver Fat%

-0.067
-0.068
P=0.359
P=0.352
Bold P-Values indicate statistical significance (P<0.05).
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-0.053
P=0.471

0.044
P=0.547

Table 5. Unadjusted univariate and multivariate logistic regression analysis displaying the relationship between covariates
and liver steatosis (All Participants)
Prevalence of
Unadjusted
P-Value
Adjusted
P-Value
Liver Steatosis
OR (95% CI)
OR (95% CI)
Age
0.996 (0.964-1.028)
0.782
0.995 (0.959-1.032)
0.786
Sex
0.833 (0.520-1.355)
0.448
0.940 (0.551-1.602)
0.820
Female (ref)
33.3%
Male
28.1%
Race/Ethnicity
White non-Hispanic
Hispanic
Black non-Hispanic
(reference)

0.598 (0.203-1.761)
1.419 (0.859-2.345)
-

0.351
0.172
-

BMI
TyG Index
Log10 HIV VL

1.118 (1.075-1.163)
3.065 (2.130-4.409)
0.718 (0.500-1.030)

<0.001
<0.001
0.072

CD4+ Count
(Per 100 Cells)

1.039 (0.934-1.155)

0.482

0.563 (0.339-0.936)

0.027

Cocaine Use
Cocaine Users
Non-Cocaine Users

4/34 (4.8%)
31/ 142 (21.8%)
49/298 (16.4%)

1.104 (1.056-1.155)
2.869 (1.960-4.200)

<0.001
<0.001

0.639 (0.367-1.114)

0.639

12.8%
20.7%

Heavy Alcohol Users
1.260 (0.733-2.166)
0.402
(AUDIT >8)
AUDIT >8
20.2%
AUDIT <8
16.7%
Bold P-Values indicate statistical significance (P<0.05). Adjusted analysis also included HIV status.
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Table 6. ANCOVA analysis comparing estimated mean TyG Index of participants with
steatosis to those without steatosis.
Estimated Means
F
P-Value
No Steatosis
8.432 ± 0.031
47.094
<0.001
Liver Steatosis
8.949 ± 0.068
Bold P-Values indicate statistical significance (P<0.05). Model controlled for HIV
infection and cocaine use.

Table 7. ROC Curve Analysis describing the relationship between TyG Index and liver
steatosis
AUC
Std. Error
95% CI
AUC ¹ 0.5
P-Value
Uninfected Controls
0.702
0.041
<0.001
0.622-0.781
N=268
PLWH
0.738
0.049
N=210
Groups Combined
0.712
0.031
Bold P-Values indicate statistical significance.

<0.001

0.642-0.834

<0.001

0.651-0.774

Table 8. Sensitivity and Specificity Analysis of TyG Risk and Liver Steatosis (PLWH
Only)
No Liver Steatosis
Liver Steatosis
Low TyG Risk <8.5938
121
10
High TyG Risk >8.5938
60
23
Sensitivity = 0.697, Specificity = 0.669
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Table 9. Comparison of the AUCs between PLWH
P-Value
Test

PLWH Only

All Participants

1

0.068

PLWH Only

Uninfected Controls
0.068
Bold P-Values indicate statistical significance (P<0.05).

1

Table 10. Chi-Square analysis showing the risk of liver steatosis in low vs. high TyG risk
categories (PLWH Only)

Prevalence of
Liver Steatosis
10/131 (7.6%)

Chi Square

Low TyG Risk
15.703
(<8.5938)
High TyG Risk 23/83 (27.7%)
(>8.5938)
Bold P-Values indicate statistical significance.

Estimate

P-Value

4.638
(2.075-10.368)

<0.001

Figure 1. Comparison of ROC Curves for PLWH and Uninfected Groups.
ROC Curves
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CHAPTER IV: THE TYG INDEX AND LIVER STEATOSIS ARE ASSOCIATED
WITH GREATER LEVELS OF IMMUNE ACTIVATION, AND LIVER FIBROSIS
BIOMARKERS IN THE MIAMI ADULT STUDIES ON HIV (MASH) COHORT
Introduction
Human Immunodeficiency Virus (HIV) Infection has been shown to disrupt
inflammatory pathways early in the course of infection.1 Individuals who start
early anti-retroviral therapy (ART) within three weeks of HIV infection maintained
greater levels of microbial translocation even though their HIV viral load (VL)
remained controlled.2 Microbial translocation promotes liver fibrosis through
activation of Kupffer cells and Hepatic Stellate Cells (HSCs).3 Activated HSCs
are associated with higher levels of tissue inhibitor of metalloproteinases (TIMPs)
which increase during fibrosis by inhibiting the breakdown of the extracellular
matrix (ECM) and not allowing fibrosis to resolve.4,5
Microbial translocation also leads directly to the secretion of pro-fibrosis
cytokines such as transforming growth factor-b (TGF-b), which promotes
collagen production6 and monocyte activation markers like soluble CD14
(sCD14) and soluble CD163 (sCD163).7,8 The relationship between microbial
translocation and immune activation is likely driven by HIV VL because
individuals on ART therapy have reduced levels of immune activation compared
to those not on ART, even though a higher level of immune activation persists
compared to uninfected individuals.9,10 Higher VL is evidence of weaker immune
function and reduced gut integrity which leads to higher levels of circulating
lipopolysaccharide (LPS) which activates the toll-like receptor-4 (TLR-4)
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pathway.11,12 In PLWH, TGF-b has become a well-established marker of liver
fibrosis;13 however, the direct effect of HIV on TGF-b is still not fully
understood.14,15 Kupffer cells produce TGF-b in the liver in response to oxidative
stress (OS), activating HSCs and increasing collagen production.16,17
In the PLWH, HIV may deplete Kupffer cells and reduce HSC activation,
but an overall inflammatory effect remains due to a decreased ability to clear
microbial translocation products from the liver.18,19 Additionally, PLWH have
reduced gut microbial diversity compared to uninfected controls.20 Damage to the
mucosa layer of the intestine from HIV infection provides another avenue for
microbial products such as LPS to leak from the intestine and travel to the liver
via the portal vein.22 The disruption of the mucosal layer is likely due to a
depletion of CD4+ cells in the gut, but also depletion of CD22.23, 24 A depleted
mucosal layer leads to increased production of inflammatory cytokines by gut
enterocytes and disruption of the tight junctions between enterocytes which
promotes a loss of gut integrity.25
Increased microbial translocation products as a result of dysbiosis or gut
endothelial damage may also contribute to NAFLD development. Visceral
adipose tissue and Kupffer cells respond to TLR-4 with increased production of
TNF-a and IL-6, both cytokines may contribute to insulin resistance (IR)26,27
which is a primary driver of NAFLD development.28 Individuals with HIV
associated NAFLD have been shown have a higher prevalence of NASH than
non-HIV associated NAFLD.29 In PLWH sCD163 has been associated with
metabolic syndrome NAFLD and liver fibrosis, likely due to the increased
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macrophage infiltration signaled from inflammatory cytokines secreted from
adipose tissue.30,31
It has been previously shown 32% of participants earlier in the MASH
Cohort were using cocaine.32 Cocaine use has been previously shown to alter
the microbial composition of PLWH.33 Altered microbial translocation, and
increased immune activation34 may explain a portion of the accelerated HIV
disease progression among crack cocaine users.35 However, complicating the
relationship between insulin resistance and immune activation is the relationship
between cocaine use and lower BMI33 which typically reflects lower insulin
resistance.
The TyG Index is a marker of insulin resistance,36 previously associated
with NAFLD.37 In PLWH, poor metabolic health has been associated with
markers of macrophage activation and fibrosis.31,32 Because PLWH are at
increased risk of immune activation38 and metabolic abnormalities,39,40 the
relationship between TyG Index, immune activation, and liver fibrosis pathways
warrants further investigation. The purpose of this study was to determine the
relationship between the insulin resistance, measured via the TyG index, and
biomarkers of immune activation and liver fibrosis in PLWH.

Methods
All participants recruited for this study were enrolled as part of the MASH Cohort.
For inclusion in the current study, participants were either free of HIV or HCV
infections (uninfected control group), or were HIV monoinfected (PLWH group).
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Participants in the MASH Cohort with HCV infection were excluded from
analysis. Participants were considered cocaine users if they stated they were
cocaine users on a drug screening questionnaire, tested positive for cocaine
metabolites through a blood draw, or positive urine toxicology screen (American
Bio Medical, Kinderhook NY). In the PLWH group, only participants who selfreported ART use in the past 6 months were included in analyses. All participants
had to be deemed eligible to complete a Magnetic Resonance Elastography
(MRE) scan to measure liver steatosis. After all inclusion and exclusion criteria
were applied, there were a total of 480 participants selected that were deemed
eligible for inclusion in the study, 211 participants in the PLWH group and 269 in
the uninfected control group. When participants were separated into four study
groups based on HIV and steatosis, Study Group 1: HIV+, Steatosis+ n=32,
Group 2: HIV+, Steatosis- n=179, Group 3: HIV-, Steatosis+ = 52, Group 4: HIV-,
Steatosis- = 217. The number of eligible participants with complete biomarker
data was more limited, for each statistical analysis, the number of participants
eligible for inclusion in that analyses are described within each result. The
methodology and analysis for this study has been approved by the IRB (Approval
# IRB-20-0273) at Florida International University.

Biomarkers of Immune Activation and Inflammation: The primary outcome
variables were analyzed by plasma collected via blood draw at FIU Borinquen
research clinic. Plasma samples were separated and stored at -80 degrees
Celsius prior to shipment to the University of Cincinnati for analyses. All
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biomarker data were quantified by analyte-specific bead-based Lumine Multiplex
immunoassays (EMD Millipore Corporation).

HIV: To be included in the PLWH, participants must have had documented HIV
infection in their medical chart. HIV VL and CD4+ counts were taken from the
most recent value documented in each participant’s medical record. ART usage
was self-reported from participants through an ART adherence questionnaire.

The TyG Index was used to approximate insulin resistance using the equation
below.36 Triglycerides and glucose were obtained via a fasted blood draw from a
trained research nurse and sent to Laboratory Corporation of America for final
analysis.
/*
/*
%&'()#* ,- . 0" 1 ∗ %&'()#* *3456'7 . 0" 1
"# $
9
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Liver steatosis: Liver steatosis was defined as >5% liver fat calculated from the
proton density fat fraction (PDFF) score from an MRE scan.41

Dietary Assessment: All participant completed a 24-hour food recall administered
at their baseline appointment. All food intake was recorded and analyzed using
NutriBase nutrient analysis software. Nutrients included in statistical analysis
total calories, total fat, saturated fat, and total cholesterol.
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Statistical Analyses
Descriptive statistics including mean and standard deviation were used to
describe participant characteristics. Differences between the participant
characteristics of the PLWH and uninfected control groups were detected using
independent t-tests for continuous variables and chi-square tests for categorical
variables. HIV VL was not normally distributed and was Log10 transformed to
bring distribution of data closer to normalization. All biomarker data were Ln
transformed to make data more normally distributed. All outcome variables were
analyzed cross-sectionally. Multiple linear regression models were performed to
detect the associations between cocaine use, TyG Index, and HIV infection with
biomarkers of immune activation, inflammation, and fibrosis. All linear regression
models included age and sex as potential confounding variables. Cocaine use,
TyG Index, and HIV status/ HIV VL were all included in linear regression models
together to detect independent associations between each independent variable
and dependent variable of interest. HIV status was used as a predictor variable
on models that included all study participants and Log 10 HIV VL was used in
analyses of PLWH only. ANCOVA analysis was used to detect differences
between biomarkers when participants were separated by HIV infection and
steatosis. All pairwise comparisons between study groups included a Bonferroni
correction to adjust for multiple comparisons. All statistical analysis were
completed using IBM SPSS version 26.
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Results
Participant characteristics and unadjusted biomarker outcomes are shown
in table 1. The PLWH group was younger than the uninfected control group
(53.18 years ± 7.57 vs. 54.85 ± 7.13, P=0.014) and also had a lower BMI (28.74
kg/m2 ± 6.05 vs. 30.05 ± 6.37, P=0.022). Unadjusted Analysis of Biomarker Data:
The only marker of monocyte or immune activation that was increased in the
PLWH group was Ln sCD27 (9.45 ± 5.01 vs. 7.58 ± 3.492, P=0.001), Ln sCD14
and Ln sCD163 were not different between PLWH and Uninfected Controls.
Compared to the uninfected group, PLWH had higher levels of both Ln TGF-Beta
(2955 ± 3958 vs. 1265 ± 1448, P=0.001) and Ln TIMP-1 (53.07 ± 21.17 vs. 45.71
± 15.44, P=0.010).
Dietary Intake: Table 2 shows there are no significant correlations
between total calories, saturated fat, total fat, or total cholesterol intake an any
biomarker analyzed in this study.
Predictors of Primary Biomarker outcomes: Table 3 and 4. Cocaine use
was association with increased levels of Ln sCD14 (β =0.216, P<0.001) and Ln
sCD27 (β = 0.176, P=0.003). Among PLWH only, cocaine use was only
associated with Ln sCD14 (β=0.184, P=0.017). Higher TyG Index values were
associated with higher levels of both Ln sCD14 (β =0.080, P<0.050) and Ln
sCD163 (β =0.164, P<0.008). Similar to analysis of all study participants, among
PLWH only, higher TyG Index values were associated with Ln sCD14 (β =0.116,
P<0.024) and Ln sCD163 (β =0.219 P<0.003). Additionally, cocaine use was
associated with higher levels of Ln sCD27 (β =0.123, P=0.011) in PLWH only.
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Among all study participants, HIV infection was associated with higher levels of
Ln sCD27 (β =0.181, P=0.005), Ln TGF- β (β = 0.915, P<0.001), and Ln TIMP-1
(β=0.118, P=0.034). Among PLWH, HIV VL was associated with higher Ln
sCD27 (β=0.181, P<0.001).
Pairwise Comparisons of Immune Activation Markers: Table 5. Mean Ln
sCD27 was greater in the HIV+, Steatosis+ group compared to group the HIV-,
Steatosis + group (2.202 ± 0.531 vs. 1.709 ± 0.604, P=0.020) and was also
greater in the HIV+, Steatosis-, group compared to group HIV-, Steatosis + group
(2.118 ± 0.468 vs. 1.709 ± 0.604). Plasma levels of Ln sCD163 were higher in
the HIV+, Steatosis+ group (6.645 ± 0.673) compared to both the HIV+, Steatosisgroup (6.178 ± 0.689, P=0.013) and the HIV-, Steatosis- group (6.084 ± 0.626,
P=0.005). For the Ln TGF- β pairwise comparisons, the HIV+, Steatosis+ group
(7.681 ± 0.729) had higher mean plasma Ln TGF- β than both the HIV-,
Steatosis+ group (6.849 ± 0.772, P<0.001) and the HIV-, Steatosis- group (6.698
± 0.899, P<0.001). Additionally, the HIV+, Steatosis- group (7.719 ± 0.692) had
higher levels of Ln TGF- β than both the HIV-, Steatosis+ group, and the HIV-,
Steatosis- groups. The mean plasma level of Ln TIMP-1 was greater in both the
HIV+, Steatosis+ (3.940 ± 0.429) and HIV+, Steatosis- groups (3.897 ± 0.362) than
the HIV-, Steatosis+ group (3.587 ± 0.473), P = 0.034 and P=0.019, respectively.
ANCOVA Analysis Comparing High Risk vs. Low Risk TyG Index Groups:
Table 6. Among PLWH, the estimated mean of Ln sCD14 among high TyG Risk
individuals was greater than the low TyG risk group (6.942 ± 0.048 vs. 6.786 ±
0.052, P=0.031). There was no difference between mean Ln sCD27 levels
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between high and low risk TyG groups. For plasma level of Ln sCD163, the high
risk TyG Index group had a higher estimated mean value than the low TyG Risk
Group (6.413 ± 0.072 vs. 6.035 ± 0.079, P=0.001).

Discussion
This study demonstrated a direct association between higher levels of
insulin resistance and immune activation in the MASH cohort. Participants with
TyG Index levels that placed them at increased risk for NAFLD, also had higher
mean levels of immune activation than participants at low risk for NAFLD, even
after controlling for HIV infection, cocaine use, age, and sex. The relationship
between higher TyG Index and increased immune activation appeared to be
even stronger in the PLWH only group, despite a smaller sample size. Consistent
with previous findings in the MASH Cohort, cocaine use was also independently
associated with immune activation among the entire study population and PLWH
group. This is likely due to alterations in gut microbial composition33 and
increased microbial translocation.34
Also consistent with previous findings of the MASH cohort and others, HIV
infection was also associated with higher levels of TGF- β42 and TIMP-143.
Among the three markers of immune activation analyzed for the current study,
HIV infection was only associated with higher levels of sCD27, not sCD14 nor
sCD163. These findings are in partial, but not full agreement with a previous
study performed by Williams et al. that found increased levels of immune
activation among all three makers in PLWH on ART.8 However, this study
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excluded participants with substance abuse than may interfere with their ability to
complete the study, it is unclear whether or not cocaine use was included in
these criteria.8 Unadjusted analysis comparing immune activation between
PLWH and Uninfected controls suggest a likely relationship between HIV
infection and immune activation in the current study as well, all three markers of
immune activation had P-Values <0.07 even though only sCD27 reached the
statistically significant threshold of P<0.05.
The finding that increased sCD27 was associated with higher HIV is
suggests HIV disease severity is also related to greater immune activation and
not simply a history of controlled HIV infection. This supports findings from
previous studies that demonstrate higher levels of immune activation even
among PLWH with highly controlled infection. Previous studies have shown an
inverse relationship between sCD27 and CD4+ count 44 and higher sCD27 may
even predict CD4+ decline.45 However, even when CD4+ count is at a healthy
level, sCD27 remains elevated in PLWH.46 Combined, these previous findings
are in agreement with our current findings that showed elevated sCD27 among
PLWH compared to uninfected controls even though our study composed mostly
of PLWH with controlled HIV VL (88.8% >200 copies/mL) and healthy CD4+ cell
counts (90.4% CD4+ >200 cells/µL). However, among the few participants with
uncontrolled VL and low CD4+ count, Log10 HIV VL was inversely associated
with sCD27.
The finding of no association between HIV infection and sCD14 contrasts
recent literature on HIV infection and microbial translocation. Increased sCD14
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levels are an immune response to circulating LPS that increases as gut integrity
is reduced.47 The high level of ART adherence, controlled HIV VL, and high CD4+
cell counts seen in the current study may explain why there was no association
between HIV infection and sCD14. However, greater TyG Index was associated
with higher levels of sCD14. This may indicate increased microbial translocation
related to poor metabolic health is a greater driver of immune activation among
PLWH with healthy immune systems. These findings are supportive of previous
work by Lemoine et al. 2017, who found increased sCD14 and sCD163 among
HIV monoinfected participants with metabolic syndrome compared to participants
without metabolic syndrome. However, this study did not have an uninfected
control group and was unable to assess the effect of the HIV infection on
sCD14.48 Increased levels of sCD14 have been shown to independently predict
mortality in PLWH,49 our findings suggest increased mortality could be related
comorbidities from poor metabolic health among people who have higher TyG
Index and controlled HIV infection.
Higher levels of TGF- β and TIMP-1 among PLWH are consistent with
previous literature.

42,50

All significant pairwise findings for TGF- β indicate the

increase was likely due to HIV infection. What is potentially novel about our
current findings, is there appears to be increased levels of TIMP-1 among PLWH
with liver steatosis compared to PLWH without steatosis, possibly indicating a
role for liver steatosis in direct fibrotic pathways and not just increased immune
activation. Among individuals with NAFLD, increased TIMP-1 levels are highly
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predictive of NASH,51 suggesting higher TIMP-1 levels among participants with

steatosis may be at greater risk of progressing to NASH.
There were no associations found between any biomarker of immune
activation or fibrosis with total caloric intake, saturated fat, total fat, or total
cholesterol intake. Dietary information was collected via 24-hr dietary recall and it
appears the ability of participants to accurately recall their dietary intake to
provide accurate diet was lacking. There is established research on the effect of
diet on the gut microbiome 52 and future studies looking more directly at this
relationship in PLWH could be beneficial.

Conclusion
The TyG Index was associated with increased levels of immune activation
markers independently of cocaine use and HIV infection. Among, PLWH
adherent to ART with healthy immune function this finding may point to metabolic
health as a primary driver of immune activation in this study population. HIV
infection was also associated with greater pro-fibrotic cytokines. Combined,
these findings suggest PLWH who have an elevated TyG Index maybe be at
increased risk of developing liver fibrosis over time.
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Table 1. Participant Characteristics

Total
N= 480

Uninfected
Controls
N=269
54.85 ± 7.13
48.3%
51.7%

P-Value

54.12 ± 7.367
46.3%F
53.8%M

HIV
Monoinfected
N=211
53.18 ± 7.57
43.6%F
56.4%M

62.1%
7.9%
29.6%

66.4%
7.1%
25.6%

58.7%
8.6%
32.7%

0.088
0.562
0.090

29. 47 ± 6.255
8.52 ± 0.654

28.74 ± 6.05
8.59 ± 0.684

30.05 ± 6.37
8.48 ± 0.63

0.022
0.069

Liver Steatosis
Prevalence

17.5%

15.2%

19.3%

0.233

Cocaine Use
Prevalence

40.6%

37.0%

43.5%

0.148

AUDIT Score

5.05 ± 6.59

4.60 ± 6.21

5.40 ± 6.87

0.185

109/480
22.7%

44/211
20.9%

65/269
24.2%

0.390

1183 ± 449.2
7.58 ± 3.492
548.8 ± 317.7
1265 ± 1448
45.71 ± 15.44

0.068
0.001
0.059
0.001
0.010

Age (years)
Sex
Race/Ethnicity
Black (non-Hispanic)
White (Non-Hispanic)
Hispanic
BMI (kg/m2)
TyG Index

AUDIT >8

Log10 HIV VL

0.014
0.303

0.759 ± 1.315

Controlled HIV VL
(<200 copies/ml)

88.8%

CD4+ (cells/µL)
CD4+ >200 cells/µL
sCD14 (ng/ml)
sCD27 (ng/ml)
sCD163 (ng/ml)
TGF- β (pg/ml)
TIMP-1 (ng/ml)

603.79 ± 382.93
90.4%
1064 ± 454.7
9.45 ± 5.01
646.4 ± 443.8
2955 ± 3958
53.07 ± 21.17

1100 ± 455.4
8.891± 4.681
617.4 ± 412.2
2441 ± 3482
50.84 ± 19.87

P-Values in bold indicate statistical significance. Data for continuous variables is presented as
mean ± STD. Statistical differences between study groups was detected using independent ttests for continuous variables and Chi-Square tests for categorical variables. BMI: Body Mass
Index, TyG Index: Triglyceride-Glucose Index, AUDIT: Alcohol Use Disorders Identification Tests,
HIV VL: HIV Viral Load, sCD14: soluble CD14, sCD27: soluble CD27, sCD163: soluble CD163,
transforming growth factor β: TGF- β, tissue inhibitor of metalloproteinases: TIMP-1.
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Table 2. Pearson Correlation between Biomarkers and Dietary Intake Variables

Total Calories
(kcal)

Saturated Fat
(g)

Total Fat (g)

sCD14

-0.094
P=0.266

-0.098
P=0.247

-0.125
P=0.138

Total
Cholesterol
(mg)
0.072
P=0.393

sCD27

-0.113
P=0.180

-0.119
P=0.157

-0.115
P=0.174

-0.104
P=0.218

sCD163

0.013
P=0.882

0.068
P=0.424

0.009
P=0.918

0.084
P=0.323

TGF- β

0.065
P=0.452

0.020
P=0.818

0.053
P=0.541

0.084
P=0.327

TIMP-1

0.049
P=0.567

0.032
P=0.708

-0.005
P=0.951

0.004
P=0.968

Bold P-Values Indicate statistical significance (P < 0.05).

Table 3. Multiple Linear Regressions showing associations between TyG Index, Cocaine use,
and HIV Infection with biomarker outcomes. (All Participants)

β

SE

t

p

sCD14
sCD27
sCD163
TGF- β
TIMP-1

0.080
0.069
0.164
0.001
-0.001

0.124
0.045
0.061
0.071
0.035

1.968
1.532
2.697
-0.255
-0.030

0.050
0.090
0.008
0.799
0.976

sCD14
sCD27
sCD163
TGF- β
TIMP-1

0.216
0.176
-0.071
-0.051
-0.048

0.059
0.065
0.088
0.104
0.051

3.658
2.052
-0.801
0.081
-0.932

<0.001
0.003
0.424
0.935
0.352

sCD14
sCD27
sCD163
TGF- β
TIMP-1

-0.060
0.181
0.123
0.915
0.118

0.064
0.064
0.096
0.103
0.055

-0.926
2.811
1.280
8.877
2.135

0.356
0.005
0.202
<0.001
0.034

TyG Index

Cocaine

HIV Infection

All models above included age, sex, TyG Index, and HIV status. Sample size for each biomarker:
sCD14: n=234, sCD27: n=234, sCD163: n=134, TGF- β: n=225, TIMP-1: n=226. Bold P-Values
Indicate statistical significance (P < 0.05).
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Table 4. Multiple Linear Regressions showing associations between TyG Index, Cocaine use,
and HIV Infection with biomarker outcomes (PLWH Only)

β

SE

t

p

sCD14
sCD27
sCD163
TGF- β
TIMP-1

0.184
0.076
-0.071
-0.058
-0.013

0.076
0.071
0.088
0.110
0.063

2.422
1.064
-0.801
-0.525
-0.016

0.017
0.289
0.424
0.601
0.841

sCD14
sCD27
sCD163
TGF- β
TIMP-1

0.116
0.123
0.219
-0.087
0.028

0.051
0.048
0.074
0.072
0.042

2.277
2.580
2.970
-1.209
0.055

0.024
0.011
0.003
0.229
0.497

sCD14
sCD27
sCD163
TGF- β
TIMP-1

-0.001
0.124
0.072
-0.031
0.031

0.027
0.026
0.040
0.040
0.023

-0.041
4.722
1.807
-0.89
0.114

0.968
<0.001
0.073
0.431
0.177

TyG Index

Cocaine

HIV VL

Sample size for each biomarker: sCD14: n=165, sCD27: n=165, sCD163: n=165, TGF- β: n=157,
TIMP-1: n=157. Bold P-Values Indicate statistical significance (P < 0.05).
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Table 5. One-Way ANOVA to analyze difference between mean biomarker values. Groups separated by HIV Status and Steatosis.
Mean Value
F
P-Value
Differences between four groups
P-Value
Ln sCD14 (ng/ml)
1.437
0.233
Groups 1 and 2 = 0.070
1.000
Groups 1 and 3 = -0.103
1.000
Group 1: HIV+, Steatosis+
6.932 ± 0.415
Groups 1 and 4 = -0.056
1.000
Group 2: HIV+, Steatosis6.863 ± 0.480
Groups 2 and 3 = -0.172
1.000
Group 3: HIV-, Steatosis+
7.034 ± 0.443
Groups 2 and 4 = -0.126
0.486
Group 4: HIV-, Steatosis6.988 ± 0.435
Groups 3 and 4 = 0.046
1.000
Ln sCD27 (ng/ml)
Group 1: HIV+, Steatosis+
Group 2: HIV+, SteatosisGroup 3: HIV-, Steatosis+
Group 4: HIV-, Steatosis-

LnTIMP-1 (ng/ml)

Groups 1 and 2 = 0.084
Groups 1 and 3 = 0.492
Groups 1 and 4 = 0.241
Groups 2 and 3 = 0.408
Groups 2 and 4 = 0.157
Groups 3 and 4 = -0.252

1.000
0.020
0.289
0.019
0.260
0.517

4.105

0.007

Groups 1 and 2 = 0.466
Groups 1 and 3 = 0.335
Groups 1 and 4 = 0.561
Groups 2 and 3 = -0.131
Groups 2 and 4 = 0.094
Groups 3 and 4 = 0.226

0.013
0.847
0.005
1.000
1.000
1.000

27.377

<0.001

Groups 1 and 2 = -0.038
Groups 1 and 3 = 0.832
Groups 1 and 4 = 0.983
Groups 2 and 3 = 0.870
Groups 2 and 4 = 1.021
Groups 3 and 4 = 0.151

1.000
0.008
<0.001
<0.001
<0.001
1.000

3.760

0.012

Groups 1 and 2 = 0.043
Groups 1 and 3 = 0.353
Groups 1 and 4 = 0.135
Groups 2 and 3 = 0.310
Groups 2 and 4 = 0.092
Groups 3 and 4 = -0.218

1.000
0.034
0.892
0.019
0.713
0.301

6.645 ± 0.673
6.178 ± 0.689
6.310 ± 0.632
6.084 ± 0.626

Ln TGF- β (pg/ml)
Group 1: HIV+, Steatosis+
Group 2: HIV+, SteatosisGroup 3: HIV-, Steatosis+
Group 4: HIV-, Steatosis-

0.005

2.202 ± 0.531
2.118 ± 0.468
1.709 ± 0.604
1.961 ± 0.493

Ln sCD163 (ng/ml)
Group 1: HIV+, Steatosis+
Group 2: HIV+, SteatosisGroup 3: HIV-, Steatosis+
Group 4: HIV-, Steatosis-

4.465

7.681 ± 0.729
7.719 ± 0.692
6.849 ± 0.772
6.698 ± 0.899

Group 1: HIV+, Steatosis+
3.940 ± 0.429
Group 2: HIV+, Steatosis3.897 ± 0.362
Group 3: HIV-, Steatosis+
3.587 ± 0.473
Group 4: HIV-, Steatosis3.805 ± 0.333
Bold P-Values Indicate statistical significance (P < 0.05).
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Table 6. ANCOVA Comparing immune activation markers between High and Low TyG Risk.

Estimated Means
sCD14 (ng/ml)
Low TyG Risk
High TyG Risk

6.786 ± 0.052
6.942 ± 0.048

sCD27 (ng/ml)
Low TyG Risk
High TyG Risk

2.093 ± 0.051
2.154 ± 0.047

sCD163 (ng/ml)
Low TyG Risk
High TyG Risk

6.035 ± 0.079
6.413 ± 0.072

P-Value
0.031

0.386

0.001

Analysis controlled for HIV status, cocaine use, age, and sex. Bold P-Values Indicate statistical
significance (P < 0.05).
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CHAPTER V: THE TYG INDEX IS ASSOCIATED WITH GREATER LIVER
STIFFNESS AND LIVER FIBROSIS IN PEOPLE LIVING WITH HIV (PLWH)
Introduction
People Living with HIV (PLWH) are 3.7x more likely to die of liver disease
than the general population.1 Non-alcoholic fatty liver disease (NAFLD) is the
most common liver disease in the world.2 Between 5-10% of individuals with
NAFLD will develop non-alcoholic steatohepatitis (NASH) and 38% of these
individuals with develop liver fibrosis.3 A previous meta-analysis found the
prevalence of NAFLD in PLWH was 35%,4 compared to 25% in the general
population.5 Another study found a higher NAFLD rate among men living with
HIV than uninfected men, but a lower NAFLD rate among women living with HIV
than uninfected women.6 Other studies have found there was no increased risk
for NAFLD in PLWH.7
Insulin resistance (IR) is one mechanism shown to increase the risk of
NAFLD and liver fibrosis.8,9 Insulin resistance increases hepatic de novo
lipogenesis10 and adipose tissue dysfunction, increasing levels of proinflammatory adipokines and cytokines,11 leading to chronic hepatic
inflammation. Insulin resistance is likely related to immune activation, which has
been shown to remain increased in PLWH even after successful antiretroviral
therapy (ART).12 The relationship between insulin resistance and NAFLD in
PLWH is noteworthy because PLWH with NAFLD have nearly twice the
likelihood of developing NASH compared to uninfected individuals.13 The
progression from NAFLD to NASH is likely facilitated by hepatic stellate cell
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(HSC) activation and proliferation. Higher levels of insulin and glucose, hallmarks
of NAFLD, increase HSC activation and connective tissue growth factor (CTGF),
both promoters of liver fibrosis.14 The activation of HSCs is also increased in
response to liver apoptosis and increased reactive oxygen species (ROS).15
The HIV virus binds to CXCR4 and CCR5 receptors which are expressed
on hepatocytes,16 activation of these receptors increases production of fibrotic
components of the extracellular matrix (ECM) proteins.17 Proteins in the HIV viral
envelop also active tissue-inhibitor metalloproteinase (TIMP) which is associated
with increased fibrosis development.18 Another component of NASH that is
distinguishable from NAFLD is the level of oxidative stress present in the liver.
Increased ROS damage mitochondrial membranes and ultimately leads
diminished mitochondrial function19,20 and increased hepatic apoptosis.21,22
Furthermore, individuals with NASH also have reduced antioxidant capacity,
which has been shown to be correlated with severity of NASH.23,24 Increased
apoptosis in NASH can be initiated by increased FFA accumulation,25,26 and
exposure to pro-inflammatory cytokines.27,28 Viral HIV envelope proteins can
also increase hepatocyte apoptosis directly or through inflammatory
pathways.29,30
Confounding the relationship between HIV infection, ROS, and apoptosis
is substance abuse. It has been previously shown 32% of selected participants
earlier in the MASH Cohort were using cocaine.31 Cocaine use has been
previously shown to induce liver injury through ROS pathways.32 Also, previous
studies from the MASH Cohort have found accelerated HIV disease progression

101

among cocaine users.31,33 Substance abuse has been described as a leading
reason to delay ART therapy34, which may further exacerbate gut mucosal
integrity issues in PLWH. Recently in the MASH Cohort cocaine use was found
to be associated with increased immune activation in the MASH Cohort.35
Due to the high level of liver disease mortality among PLWH, it is
important to understand the interaction between multiple physiological and
lifestyle factors that may lead to liver disease in this population. Poor metabolic
health has been previously associated with greater liver fibrosis development in
PLWH9 however, to the best of our knowledge there are no studies that have
looked directly at the effect of insulin resistance and liver steatosis on the
likelihood of liver fibrosis in PLWH in the context of cocaine use. Therefore, the
purpose of this study was to determine the association between two markers of
metabolic health, insulin resistance via the TyG Index, and liver steatosis, on
oxidative stress, hepatic apoptosis, and liver fibrosis in the MASH Cohort.

Methods
The data in this cross-sectional study was derived from a subset of participants in
the Miami Adult Studies on HIV (MASH) cohort and included PLWH and an
uninfected control group. Individuals with Hepatitis C Virus (HCV) were excluded
from analysis. Eligibility for inclusion included the ability to participate in a liver
scan using Magnetic Resonance Elastography (MRE) Imaging to determine liver
stiffness and Proton Density Fat Fraction (PDFF) for liver fat. Exclusion criteria
for MRE imaging included any presence of metal in the body, claustrophobia,
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and excessively high obesity that mechanically obstructed the technician’s ability
to perform the scan. Cocaine use was confirmed through self-report
questionnaire, blood metabolites or urine toxicology (American Bio Medical,
Kinderhook NY). After application of all exclusion criteria, 480 participants were
eligible for final analysis, 211 in the PLWH and 269 in the uninfected group.
When participants were separated by HIV infection and steatosis status, Study
Group 1: HIV+, with steatosis = 32, Group 2: HIV +, no steatosis = 179, Group 3:
HIV- with steatosis = 52, Group 4: HIV-, no steatosis = 217. Not all participants
were able to be analyzed for each outcome biomarker, participants with missing
data were not included in analysis. All participants provided their written consent
to participate in the study and the study was approved by the IRB (approval #
IRB-20-0273) at Florida International University.

Anthropometrics: Height, weight, waist circumference, and BMI were obtained by
trained research staff. Patients most recent medical records were used to confirm
HIV status and abstract values for CD4+ and HIV VL. Blood draws were
completed to collect fasting triglycerides and fasting glucose,

Insulin resistance: The Triglyceride-glucose index (TyG Index) equation was
calculated using the following equation:36
.)
.)
$%&'(") +, - /! 0 ∗ $%&'(") )2345&6 - /! 0
!" #
8
2
MRE Variables: Liver fat % was calculated from MR scans using the fat to water
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ratio that is produced by the MRI-PDFF value using the following equation.37
[100 ∗ (=%' '5 >%'6? @%'(5]
[1 + (=%' '5 >%'6? @%'(5)]
Liver fat % >5% is considered evidence for liver steatosis.36 Liver fibrosis, was
assessed from magnetic resonance elastography (MRE) scans. MRE values
<2.5 kilopascals (kPa) are indicative of a healthy liver, 2.5-2.9kPa indicates
normal liver with possible inflammation, > 2.9kPa indicates liver fibrosis.38

Dietary Assessment: During their baseline interview each participant completed a
24-hour dietary recall. All reported food intake was recorded using NutriBase
nutrient analysis software. Statistical analyses were completed on the following
nutrients: total calories, total fat, saturated fat, and total cholesterol.

Biomarker Data: All glutathione variables were measured using Enzyme Linked
ImmunoELISA kits (Arbor Assays, 1514 Eisenhower Place, Ann Arbor MI,
48108). Samples are prepared by mix 200ml of whole blood with 200ml of
sulfosalicylic acid. Samples were stored at -80 degrees C and thawed
immedaitely before analysis performed to manufactorers instructions. 8-oxo-2’deoxyguanosine (8-oxo-dG) DNA must be extracted from peripheral blood
mononuclear cells (PBMCs) using ReliaPrep Blood gDNA Miniprep System
(Promega). PBMCs are thawed from the -80 degrees Celsius freezer and
washed with phosphate buffered saline and RPMI solutions. After DNA is
extracted the concentration of DNA is measured using a spectrophotometer. The
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DNA concentration of each sample is used to calculate the volume needed for
formamidopyrimidine DNA glycosylase (FPG) enzyme treatment for samples.
The FPG enzyme repairs oxidized DNA bases, especially purines such as 8-oxodG. For each participant included in analysis there were duplicate DNA samples
that remained untreated and duplicate samples treated with the FPG Enzyme.
The samples were mixed with SYBR Green mix and amplified using qPCR (BioRad) and threshold cycle values (Ct) were obtained for both treated and
untreated samples. The mean difference in Ct values (Ctunt-Cttrt) represents the
amount of 8-oxo-dG in the sample. Apoptosis is being measured via a Human
CK 18 (Cytokeratin 18)-M30 sandwich enzyme-linked immune-sorbent assay
(ELISA) kit (XpressBio). Each well is pre-coated with Anti-CK 18-M30 antibody.
Biotin conjugated ant-CK 18-M30 antibody is used as a detection reagent.
Standard reagents, samples, and Biotin reagent are also added to each well and
then washed away with wash buffer. HRP-Streptavidin reagent is then added and
all unbound conjugates are washed away from the plate. TMB substrate is used
to produce a bright color in each well that can be detected by a microplate reader
to calculate CK 18-M30 concentration.

Statistical Analysis
Statistical analysis was completed using IBM SPSS 26 software. All demographic
variables and participant characteristics were reported as mean ± STD for
continuous variables and categorical variables were reported as a percentage of
cases. For unadjusted analysis of continuous outcome variables independent t-
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tests were performed, unadjusted categorical group differences were detected
with Chi-Square tests. One-Way ANOVA was performed to detect differences
across the four study groups separated by HIV and steatosis status, and HIV and
TyG Risk category. All post-hoc pairwise analysis included Bonferroni corrections
to adjust for multiple comparisons. Multiple linear regression was performed to
determine independent associations between primary independent and
dependent variables of interest. Simple and multivariate logistic regression was
performed to assess the relationship between TyG Index and liver fibrosis. All
multiple linear and logistic regressions were adjusted for Age, Sex, BMI, HIV
Status, and Cocaine Use.

Results
Participant characteristics are described in table 1. The mean age of this
selected MASH cohort sample was 54.12 ± 7.367 years, the PLWH group was
significantly younger than the uninfected control group (53.18 ± 7.574 vs. 54.85 ±
7.129, P=0.014). The mean BMI of all participants was 29.47 ± 6.255, the PLWH
group had a significantly lower BMI compared to the uninfected control group
(28.74 ± 6.05 vs. 30.05 ± 6.365, P = 0.022). This study enrolled a slightly higher
number of males (53.8%) than females. The racial/ethnic makeup of the study
was predominantly Black non-Hispanic (62.1%), and 29.6% of the cohort
identified as Hispanic. The prevalence of cocaine use among all participants was
40.6%. The prevalence of liver steatosis and fibrosis was 17.5% and 9.2%
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respectively. Among PLWH, the number of participants with controlled HIV VL

(<200 copies/mL) was 88.8%).
Dietary Intake Variables: Tables 2 and 3. Pearson correlation analysis
found Total Calories, Total Fat, and Saturated Fat were all positively associated
with increased liver apoptosis (P<0.05). When multiple regression analyses were
performed that controlled for Age, Sex, BMI, Cocaine Use, and HIV Status, only
saturated fat remained associated with increased apoptosis (β=3.26, P=0.050).
Unadjusted analysis found no difference between hazardous alcohol drinkers
and non-hazardous drinkers for mean 8-oxo-dG, Total GSH, Free GSH,
Apoptosis, or Liver Stiffness (data not shown).
Unadjusted Oxidative Stress, Apoptosis, and Liver Stiffness Analysis:
Table 4. Free glutathione (GSH) and Total Glutathione (Total GSH) were both
higher among cocaine users than non-users [1045.3 ± 343.5 vs. 945.9 ± 339.9,
P=0.002] and (1079.1 ± 344.9 vs. 978.9 ± 339.5, P=0.002), respectively. There
was also decreased levels of hepatic apoptosis among cocaine users than nonusers (1022.6 ± 324.6 vs. 1115.0 ± 434.2, P=0.050). There were no differences
between liver fibrosis rates or 8-oxo-dG levels between cocaine users vs. nonusers. Participants with liver steatosis had greater mean liver stiffness than
participants without liver steatosis (2.459 ± 0.698 vs. 2.284 ± 0.471, P=0.005).
There were no differences in liver fibrosis rates or 8-oxo-dG levels between
steatosis groups. Participants with TyG Index values that placed them at high risk
for liver steatosis had lower GSH (919.6 ± 286.5 vs. 1003.4 ± 355.6, P=0.015)
and Total GSH (952.2 ± 289.4 vs. 1036.8 ± 355.5, P=0.014) than participants
with low steatosis risk TyG Index values. Additionally, the high steatosis risk TyG
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Index group had increased levels of liver stiffness compared to the low steatosis
risk group (2.416 ± 0.67 vs. 2.290 ± 0.71, P=0.033). Levels of 8-oxo-dG were no
different when compared between TyG Risk groups (P=0.868).
One-Way ANOVA Across HIV and Steatosis Groups: Table 5. Total GSH,
F=4.081, P=0.007; Free GSH, F=4.216, P-Value=0.006, and Liver Stiffness,
F=3.647, P=0.013 were all different across groups. For Total GSH, pairwise
analysis found the HIV+, Steatosis- group had lower Total GSH compared to the
HIV-, Steatosis- group (969.10 vs. 1073.09, P=0.016). For Free GSH, pairwise
analysis found the HIV+, Steatosis- Group had lower Free GSH compared to the
HIV-, Steatosis- Group (935.54 vs. 1040.14, P=0.015). For Liver Stiffness, the
HIV+, Steatosis+ Group (2.588 kPa) had higher liver stiffness measurements than
both the HIV+, Steatosis- Group (2.588 vs. 2.283 kPa, P=0.015) and the HIV-,
Steatosis- Group (2.588 kPa vs. 2.285, P=0.014).
One-Way ANOVA Across HIV and TyG Risk Groups: Table 6. When
participants were separated by HIV and TyG Risk, Total GSH, F=5.985, P=0.001;
Free GSH, F=6.088, P<0.001, and Liver Stiffness, F=3.682, P=0.012 were all
different across groups. Pairwise analysis found the HIV+, Low TyG Risk group
had lower Total GSH compared to the HIV-, Low TyG Risk group (965.38 vs.
1092.40, P=0.016) and the HIV-, High TyG Risk Group had a lower Total GSH
compared to the HIV-, Low TyG Risk Group (953.00 vs. 1092.40, P=0.041). The
HIV+, Low TyG Risk Group had lower Free GSH compared to the HIV-, Low TyG
Risk Groups (918.85 vs. 1059.70, P=0.002). The HIV-, High TyG Risk Group had
lower Free GSH compared to the HIV-, Low TyG Risk Group (920.18 vs.
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1059.70, P=0.040). The HIV+, High TyG Risk Group had greater mean liver
stiffness (2.557 kPa) than either than HIV-, Low TyG Risk Group (2.557 kPa vs.
2.270, P=0.007) or the HIV-, Low TyG Risk Group (2.557 kPa vs. 2.306,
P=0.021).
Regression Analysis of Primary Outcomes: Tables 7 and 8. Higher TyG
Index was associated with increased liver stiffness in (β = 0.118, P=0.002).
Higher TyG Index appeared to be associated with both lower Free GSH and
greater hepatic apoptosis (each association had a P-Value <0.010), but neither of
these values reached the threshold of statistical significance for this study.
Cocaine use was associated with greater levels of Free GSH (β=88.00, P=0.006)
and increased hepatic apoptosis (β= 94.62, P=0.050). HIV infection was
associated with reduced levels of Free GSH (β= -95.24, P=0.003). Among
PLWH, the TyG Index was associated with increased likelihood of liver fibrosis in
unadjusted [OR=2.593 (1.442, 4.664), P=0.001], partially adjusted [OR=2.557
(1.403, 4.661), P=0.002] and fully adjusted [OR=2.718 (1.469, 5.028), P=0.001)
logistic regression models. Similarly, among all participants the TyG Index was
associated with increased likelihood of liver fibrosis in unadjusted [OR=1.610
(1.042, 2.490), P=0.032], partially adjusted [OR=1.628 (1.042, 2.542), P=0.032]
and fully adjusted [OR=1.619 (1.027, 2.553), P=0.046) models.

Discussion
The primary finding of this study is the TyG Index was a significant
predictor of liver fibrosis among PLWH only and in the combined MASH Cohort.
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Additionally, HIV infection was associated with reduced levels of both Free GSH
(P=0.003) and Total GSH (P=0.003). Interestingly cocaine use was associated
with increased hepatic apoptosis (P=0.050), but also increased Free GSH and
Total GSH (P=0.006) and (P=0.005) respectively. The TyG index also trended
towards being associated with reduced Free GSH, Total GSH, and increased
hepatic apoptosis, but these findings did not reach the statistically significant
threshold of P<0.05.
The TyG Index appeared to be a stronger predictor of fibrosis in PLWH
only and this finding may highlight the “multiple hit hypothesis” of NASH that has
been previously discussed a mechanism of liver fibrosis development.39
Increased insulin resistance represents an additional stressor to the liver on top
of HIV infection, ART use, and possible substance use and food insecurity, all
factors that have been previously associated with liver fibrosis.40-42 Previous
research has found an association between HIV monoinfection and increased
FIB-4 score;43 however, our study did not find an independent association
between HIV and liver fibrosis. The effect of the HIV virus may have been difficult
to assess because the PLWH were younger and had lower BMI compared to the
control group. The overall prevalence of fibrosis in this study was also lower than
typically reports in cohorts of HIV monoinfection.44-46
Pairwise analysis found participants with both HIV and High TyG Risk had
increased liver stiffness compared to participants without HIV and low TyG Risk.
This finding indicates a potential cumulative effect of HIV infection and IR on liver
stiffness. Previous studies have found also found an association between IR and
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liver fibrosis,9 but were unable to compare fibrosis risk in both PLWH and
uninfected controls. Another study found increased risk of liver fibrosis among
individuals with metabolic syndrome, but neither IR or steatosis severity were
associated with increased fibrosis risk.46
This study found HIV infection was associated with reduced levels of Free
GSH and Total GSH. This supports previous findings of the MASH Cohort that
found higher levels of oxidative stress among PLWH.47 Increased oxidative
stress is one pathway of HSC activation that leads to the deposition of fibrotic
proteins.48 Conversely, cocaine use was associated with higher Free GSH and
Total GSH. This appears to contradict previous literature in animal studies.49
However, there were fewer cocaine users among PLWH and cocaine use was
associated with decreased odds of liver steatosis (data not shown) which may
indicate pro-oxidative stress pathways in cocaine users may be been suppressed
due to other factors. Previous studies have found reduced levels of glutathione
among participants with NAFLD,50 in our study, higher TyG Index appeared to be
related to lower Free GSH, but this result did not reach statistical significance.
Patients with NAFLD may have lower reduced glutathione as a result of
increased production of ROS that scavenges glutathione storage.51
Dietary fat intake has been previously shown to be associated with
increased liver fat content and upregulation of hepatic apoptosis pathways.52 Our
study found a positive association between saturated fat intake and hepatic
apoptosis, but no relationship between saturated fat intake and liver fat content
(data not shown). The mechanistic link between saturated fat intake and
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apoptosis has been previously attributed to increased hepatic fat content and
ROS,53 but this finding is not support by our own data that found no relationship
between saturated fat intake and oxidative stress (data not shown). Most
previous studies analyzing hepatic apoptosis outcomes have been in animal
models. Further investigation into the relationship between saturated fat intake
and hepatic apoptosis is necessary to understand this relationship with more
clarity.

Conclusion
Higher TyG Index is associated with greater likelihood of liver fibrosis
among PLWH and among MASH cohort participants overall. In this cohort of
participants with a high rate of ART adherence and well-controlled HIV VL,
insulin resistance and metabolic health overall may act as a primary driver of liver
disease. Future studies should continue to monitor the relationship between high
TyG Index values and liver fibrosis development and progression over time.
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Table 1. Participant Characteristics
Total
N= 480
54.12 ± 7.367

PLWH
N-211
53.18 ± 7.574

Uninfected Controls
N=269
54.85 ± 7.129

P-Value

46.2% F
53.8% M

43.6% F
56.4% M

48.3%
51.7%

0.303

62.1%
7.9%
29.6%

66.4%
7.1%
25.6%

58.7%
8.6%
32.7%

0.088
0.562
0.090

29.47 ± 6.255
8.52 ± 0.654

28.74 ± 6.05
8.585 ± 0.684

30.05 ± 6.365
8.475 ± 0.628

0.022
0.069

84/480
(17.5%)

32/211
(15.2%)

52/269
(19.3%)

0.233

Liver Fat %
Cocaine Use
Prevalence

4.25 ± 4.43
195/580
(40.6%)

3.932 ± 3.694
78/211
(37.0%)

4.499 ± 4.930
117/269
(43.5%)

0.150
0.148

AUDIT Score

5.05 ± 6.59

4.60 ± 6.21

5.40 ± 6.87

0.185

109/480
22.7%

44/211
20.9%

65/269
24.2%

0.390

Log10 HIV VL

-----

0.759 ± 1.315

-----

-----

Controlled HIV VL
(<200 copies/ml)

-----

88.8%

-----

-----

CD4+ (cells/µL)
CD4+ >200 cells/µL

---------

604.59 ± 381.14
90.4%

---------

---------

986.35 ± 344.50
33.34 ± 23.10
3.76 ± 3.33
1019.69 ± 344.90
1059.14 ± 373.75

927.0 ± 330.4
34.13 ± 23.32
4.101 ± 3.527
961.1 ± 340.2
1083.1 ± 370.5

1033.1 ± 341.9
32.71 ± 22.94
3.495 ± 3.138
1065.8 ± 342.2
1021.9 ± 377.5

0.001
0.505
0.048
0.001
0.195

8-oxo-dG
(Ct2-Ct1)

0.24 ± 0.52

0.219 ± 0.462

0.261 ± 0.552

0.669

Liver Stiffness (kPA)

2.31 ± 0.52

2.328 ± 0.546

2.304 ± 0.501

0.614

Age
Sex
Race/Ethnicity
Black (non-Hispanic
White (Non-Hispanic)
Hispanic
BMI (kg/m2)
TyG Index
Liver Steatosis
Prevalence

AUDIT >8

Free GSH (µM)
GSSG(µM)
% GSSG
Total GSH (µM)
Apoptosis (U/L)

0.014

Liver Fibrosis
44/478
22/210
22/268
0.395
Prevalence
(9.2%)
(10.5%)
(8.2%)
P-Values in bold indicate statistical significance (P <0.05). Data for continuous variables is presented as
mean ± STD. Statistical differences between study groups was detected using independent t-tests for
continuous variables and Chi-Square tests for categorical variables. BMI: Body Mass Index, TyG Index:
Triglyceride-Glucose Index, HIV VL: HIV Viral Load, Free GSH: reduced glutathione, GSSG: oxidized
glutathione, Total GSH: total glutathione.
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Table 2. Pearson Correlation between Dietary Intake Variables, Oxidative Stress, Apoptosis, and
Liver Stiffness

Total Calories
(kcal)

Saturated Fat
(g)

Total Fat (g)

8-oxo-dG
(Ct2-Ct1)

0.118
P=0.430

0.074
P=0.623

0.100
P=0.503

Total
Cholesterol
(mg)
0.065
P=0.663

Total GSH

-0.107
P=0.141

-0.074
P=0.307

-0.099
P=0.191

-0.026
P=0.722

Free GSH

-0.100
P=0.168

-0.701
P=0.332

-0.096
P=0.186

-0.030
P=0.683

Apoptosis

0.162
P=0.045

0.176
P=0.030

0.168
P=0.038

0.030
P=0.712

Mean Liver
Stiffness

0.010
P=0.895

0.008
P=0.909

0.001
P0.990

0.083
0.257

Bold P-Values Indicate statistical significance (P < 0.05).

Table 3. Multiple Linear Regression models showing associations between Dietary
Variables and Hepatic Apoptosis.
Total Calories (kcal)
Total Fat (g)
Saturated Fat (g)

β

SE

t

p

0.045
1.158
3.26

0.026
0.600
1.634

1.699
1.930
1.980

0.092
0.056
0.050

Bold P-Values Indicate statistical significance (P < 0.05). All models adjusted for Age, Sex, BMI,
Cocaine, and HIV status.
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Table 4. Unadjusted Comparisons of Oxidative Stress, Apoptosis, Liver Stiffness and Fibrosis
Coc+
CocP
Steat+
SteatP
Low TyG
Free GSH
1045.3 ±
945.9 ±
0.002
955.3 ±
992.9 ±
0.367
1003.4 ±
343.5
339.9
306.0
352.0
355.6
(µM)

High TyG
919.6 ±
286.5

P
0.015

GSSG
(µM)

33.80 ±
23.24

33.03 ±
23.04

0.720

33.87 ±
17.80

33.23 ±
24.08

0.819

33.39 ±
24.60

32.65 ±
15.82

0.776

% GSSG

3.487 ±
2.825

3.951 ±
3.621

0.134

3.951 ±
3.428

3.722 ±
3.306

0.569

3.742 ±
3.487

3.773 ±
2.542

0.934

Total GSH
(µM)

1079.1 ±
344.9

978.9 ±
339.5

0.002

989.2 ±
306.7

1026.1 ±
352.4

0.376

1036.8 ±
355.5

952.2 ±
289.4

0.014

Apoptosis
(U/L)

1115.0 ±
434.2

1022.6 ±
324.6

0.050

1140.2 ±
368.2

1044.2 ±
373.7

0.131

1042.2 ±
367.1

1125.0 ±
398.9

0.146

8-oxo-dG
(Ct2-Ct1)

0.300 ±
0.471

0.223 ±
0.533

0.474

0.177 ±
0.527

0.261 ±
0.515

0.491

0.234 ±
0.532

0.250 ±
0.505

0.868

Liver Stiffness
(kPa)

2.300 ±
0.403

2.325 ±
0.588

0.589

2.459 ±
0.698

2.284 ±
0.471

0.005

2.290 ±
0.71

2.416 ±
0.67

0.033

Liver
62/194
82/284
0.470
31/83
Fibrosis
(32.0%)
(28.9%)
(37.3%)
Bold P-Values indicate statistical significance (P <0.05).

113/395
(28.6%)

0.115

69/238
(29.0%)

75/238
(31.5%)

0.549
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Table 5. One-Way ANOVA. Groups separated by HIV Status and Steatosis (All Post-Hoc Analysis included Bonferroni Correction)
Mean Value
F
P-Value
Differences between four groups
P-Value
4.081
0.007
Groups 1 and 2: -52.51
1.000
Total GSH (µM)
Groups 1 and 3: -118.13
0.755
Group 1: HIV+, Steatosis+
916.59
Groups 1 and 4: -156.50
0.096
Group 2: HIV+, Steatosis969.10
Groups 2 and 3: -65.62
1.000
Group 3: HIV-, Steatosis+
1034.72
Groups 2 and 4: -104.00
0.016
Group 4: HIV-, Steatosis1073.09
Groups 3 and 4: -38.38
1.000
Free GSH (µM)
Group 1: HIV+, Steatosis+
Group 2: HIV+, SteatosisGroup 3: HIV-, Steatosis+
Group 4: HIV-, Steatosis-

Liver Stiffness (kPa)

0.006

Groups 1 and 2: -56.28
Groups 1 and 3: -123.77
Groups 1 and 4: -160.88
Groups 2 and 3: -67.49
Groups 2 and 4: -104.60
Groups 3 and 4: -37.11

1.000
0.650
0.078
1.000
0.015
1.000

1.547

0.203

Groups 1 and 2: 66.16
Groups 1 and 3: 0.08
Groups 1 and 4: 145.10
Groups 2 and 3: -66.08
Groups 2 and 4: 78.93
Groups 3 and 4: 145.02

1.000
1.000
0.631
1.000
0.762
0.760

3.647

0.013

879.26
935.54
1003.03
1040.14

Apoptosis (U/L)
Group 1: HIV+, Steatosis+
Group 2: HIV+, SteatosisGroup 3: HIV-, Steatosis+
Group 4: HIV-, Steatosis-

4.216

1140.21
1074.05
1140.13
995.11

Groups 1 and 2: 0.305
0.015
Groups 1 and 3: 0.207
0.471
Group 1: HIV+, Steatosis+
2.588
Groups 1 and 4: 0.303
0.014
Group 2: HIV+, Steatosis2.283
Groups 2 and 3: -0.098
1.000
Group 3: HIV-, Steatosis+
2.382
Groups 2 and 4: -0.002
1.000
Group 4: HIV-, Steatosis2.285
Groups 3 and 4: 0.096
1.000
Bold P-Values indicate statistical significance (P <0.05). Models shown above did not control for any covariates due to smaller sample sizes when
separated into four study groups. Group 1: 32, Group 2: 179, Group 3: 52, Group 4: 217.
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Table 6. One-Way ANOVA. Groups separated by HIV Status and TyG Risk (All Post-Hoc Analysis included Bonferroni Correction)
Mean Value
F
P-Value
Differences between four groups
P-Value
5.985
0.001
Groups 1 and 2: -14.09
1.000
Total GSH (µM)
Groups 1 and 3: -1.706
1.000
Group 1: HIV+, High TyG
951.29
Groups 1 and 4: -141.10
0.069
Group 2: HIV+, Low TyG
965.38
Groups 2 and 3: 12.39
1.000
Group 3: HIV-, High TyG
953.00
Groups 2 and 4: -127.01
0.002
Group 4: HIV-, Low TyG
1092.40
Groups 3 and 4: -139.40
0.041
Free GSH (µM)
Group 1: HIV+, High TyG
Group 2: HIV+, Low TyG
Group 3: HIV-, High TyG
Group 4: HIV-, Low TyG

Liver Stiffness (kPa)

<0.001

Groups 1 and 2: -12.25
Groups 1 and 3: -1.34
Groups 1 and 4: -140.86
Groups 2 and 3: 10.92
Groups 2 and 4: -128.60
Groups 3 and 4: -139.52

1.000
1.000
0.069
1.000
0.002
0.040

1.477

0.221

Groups 1 and 2: 48.17
Groups 1 and 3: -10.65
Groups 1 and 4: 128.26
Groups 2 and 3: -58.83
Groups 2 and 4: 80.08
Groups 3 and 4: 138.91

1.000
1.000
0.604
1.000
0.788
0.777

3.682

0.012

918.85
931.10
920.18
1059.70

Apoptosis (U/L)
Group 1: HIV+, High TyG
Group 2: HIV+, Low TyG
Group 3: HIV-, High TyG
Group 4: HIV-, Low TyG

6.088

1121.80
1073.62
1132.45
993.54

Groups 1 and 2: 0.288
0.007
Groups 1 and 3: 0.256
0.090
Group 1: HIV+, High TyG
2.557
Groups 1 and 4: 0.252
0.021
Group 2: HIV+, Low TyG
2.270
Groups 2 and 3: -0.032
1.000
Group 3: HIV-, High TyG
2.302
Groups 2 and 4: -0.036
1.000
Group 4: HIV-, Low TyG
2.306
Groups 3 and 4: -0.003
1.000
Bold P-Values indicate statistical significance (P <0.05). Models shown above did not control for any covariates due to smaller sample sizes when
separated into four study groups. Group 1: 45, Group 2: 165, Group 3: 55, Group 4: 213.
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Table 7. Multiple Linear Regression showing associations between TyG Index, Cocaine
Use, and HIV Infection with primary outcomes.
β
SE
t
p
Free GSH
TyG Index
-40.60
24.52
-1.656
0.098
Cocaine Use
88.00
31.88
2.761
0.006
HIV Status
-95.24
31.75
-3.000
0.003
Total GSH
TyG Index
Cocaine Use
HIV Status

-39.73
89.20
-93.60

24.57
31.95
31.82

-1.617
2.792
-2.942

0.107
0.005
0.003

Apoptosis
TyG Index
Cocaine Use
HIV Status

64.46
94.62
58.39

36.51
48.11
38.52

1.766
1.967
1.203

0.079
0.050
0.230

Liver Stiffness
TyG Index
Cocaine Use
HIV Status

0.118
-0.001
0.023

0.038
0.049
0.049

3.100
-0.017
0.472

0.002
0.986
0.637

Bold P-Values indicate statistical significance (P <0.05). All Models Adjusted for Age, Sex, and
BMI. Free GSH (n=276), Total GSH (n=476), Apoptosis (n=261), Liver Stiffness (n=475).
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Table 8. TyG Index predicts liver fibrosis in both PLWH and combined study groups.
TyG Index
Unadjusted

PLWH Only
(n=211)
2.593
(1.442, 4.664)
2.557
(1.403, 4.661)
2.718
(1.469, 5.028)

P Value
0.001

Adjusted for age, sex,
0.002
and BMI
Adjusted for age, sex,
0.001
BMI, Cocaine and HIV
VL
Bold P-Values indicate statistical significance (P <0.05).
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All Participants
(n=476)
1.610
(1.042, 2.490)
1.628
(1.042, 2.542)
1.593
(1.009, 2.515)

P Value
0.032
0.032
0.046
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Chapter VI: SUMMARY OF CONCLUSIONS AND IMPACT ON PRACTICE
This study investigated the ability of the triglyceride-glucose (TyG) Index
to predict liver steatosis in people living with HIV (PLWH) and the association
between the TyG Index and biomarkers of immune activation, inflammation,
oxidative stress, and liver fibrosis in the Miami Adult Studies on HIV (MASH)
cohort.
Over the past two decades, the disease burden of PLWH has shifted from
advanced immunodeficiency syndrome (AIDS), to a disease that has been
correlated with similar chronic disease states as seen in the general population.1
The MASH Cohort has been closing studying the relationship been HIV infection
and liver disease for over a decade, and we know that PLWH are more than 3.7x
more likely to die of liver disease than individuals in the general population.2 The
most common form of liver disease in the world is non-alcoholic fatty liver
disease (NAFLD), also known as liver steatosis. Previous estimates have
reported around 35% of PLWH have steatosis compared to 25% of the general
population.3 The presence of steatosis increases the likelihood of individuals
developing liver fibrosis.4 In PLWH in particular, these individuals present a
unique set of risk factors that may explain the increased risk of liver steatosis and
fibrosis in this population; direct effects of from HIV infection, anti-retroviral
therapy (ART) related hepatotoxicity, food insecurity, and substance abuse.5-10
The gold standards of measuring liver steatosis are liver biopsy and
magnetic resonance imaging-protein density fat fraction (MRI-PDFF) score. Each
of these measures can be invasive, expensive, and difficult to apply to a large
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population. This study found the TyG Index was a good predictor of liver
steatosis in both PLWH and uninfected controls. Similar findings have been
previously shown in HBV-HIV coinfected adults, but not among HIV
monoinfected individuals.11 Our study found identified a TyG Index score of
8.5938 as the optimal cut-off value to distinguish between individuals with and
without liver steatosis in PLWH, the sensitivity of this value = 0.697 with a
specificity of 0.669. The total area under the curve (AUC) of the ReceiverOperator Curve (ROC) was marginally higher in the PLWH compared to the
uninfected control group (P=0.068). In PLWH, participants with a TyG Index
score >8.5835 were 4.638x more likely to have liver steatosis than participants
with TyG Index scores < 8.5835.
It has been previously shown that PLWH have increased levels of
microbial translocation by through activation of Kupffer cells and Hepatic Stellate
Cells (HSCs) in the liver.12,13 Greater microbial translocation activation is
associated with both increased metabolic syndrome and lipid accumulation in the
liver14 while simultaneously activating pro-fibrotic pathways.15,16 Markers of
immune activation related to increased microbial translocation include sCD14
and sCD163,17 both of which were increased in the current study. Liver fibrosis
pathway markers TGF-b and TIMP-1 were also increased among PLWH in the
current study, suggesting the HIV virus actives collagen deposition pathways18,19
and inhibits the breakdown of extracellular matrix (ECM) proteins.20,21
In multiple regression analysis, the TyG Index was associated with both
sCD14 (β =0.080, P=0.050) and sCD163 (β = 0.164, P=0.008). We found HIV
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infection was associated with both increased immune activation and fibrosis
pathway markers. Increased plasma levels of sCD27 (β = 0.181, P=0.005), TGFb, (β =0.915, P<0.001) and TIMP-1 (β = 0.118, P=0.034) were all associated with
HIV infection. Furthermore, among PLWH only, higher HIV VL was associated
with increased sCD27 (β=0.124, P<0.001). Together, these findings indicate
even well controlled HIV infection is associated with immune activation but more
severe HIV disease also contributes to increased immune activation as well.
Cocaine was associated with increased levels of sCD14 (β = 0.116, P=0.024),
sCD27 (β=0.123, P=0.011), and sCD163 (β =0.219, P=0.003), consistent with
previous MASH cohort findings.22
Previous studies have found IR14 and metabolic syndrome23 to be
associated with liver fibrosis in PLWH. However, to the best of our knowledge,
there have not been any studies that have measured IR using the TyG Index.
Because the TyG Index has been previously shown to be a better predictor of
NAFLD than HOMA-IR, and it is calculated using only fasting triglycerides and
glucose, both laboratory values typically obtain at a routine health screening, we
chose to examine the relationship between TyG Index and liver fibrosis. Chapter
3 of this work found the TyG Index value of 8.5938 was an optimal cut-off value
to determine steatosis risk in PLWH. We found High TyG risk was associated
with greater liver stiffness (P=0.012) in PLWH. We also found HIV infection was
associated with lower levels of Free GSH (β= -95.24, P=0.003) and Total GSH
(β= -93.60, P=0.003), consistent with previous MASH Cohort findings of
increased oxidative stress among PLWH.24
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In conclusion, we found the TyG Index can be a good proxy measurement
for estimating steatosis risk in PLWH. When used either as a marker of insulin
resistance or liver steatosis, higher TyG Index levels are indicative of poor
metabolic health. This study found the TyG Index was associated with both
immune activation and liver fibrosis in the MASH Cohort. It also appears as
though there may be an association between increased TyG Index and lower
Total Glutathione as well. The current MASH cohort sample consistent of PLWH
with high rates of ART adherence and well controlled HIV disease. These
individuals have a higher risk of developing cardiometabolic co-morbidities than
HIV-AIDS related health issues, therefore the focus on the TyG Index as a
determinant of liver disease is representative of a concern that many PLWH are
living with. These findings suggest the TyG Index as a marker of metabolic health
is a primary determinant of liver disease outcomes in PLWH. This index is an
easy to obtain measurement that can be primary treatment target among
healthcare practitioners in the prevention of liver disease.
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CHAPTER VII: FUTURE RESEARCH
Our study demonstrated the TyG Index was a good predictor of liver
steatosis, and was associated with immune activation and liver fibrosis in PLWH.
However, many biomarkers analyzed in this study including sCD14, sCD27,
sCD163, TGF-b, TIMP-1 and hepatic apoptosis had a more limited sample size
than liver steatosis and fibrosis measurements and appeared to be statistically
underpowered. Continuing to analyze more participants in the MASH Cohort and
improving the statistical power to detect differences between study groups would
provide extensive value towards understanding the relationship between
metabolic health and liver disease in PLWH. Furthermore, this work used only
cross-sectional analysis, the COVID-19 pandemic ceased the ability of the MASH
Cohort research team to continuously collect data on the development of liver
fibrosis. Future MASH Cohort studies should compare participants with high TyG
Risk at baseline to participants with low TyG Risk and compare the likelihood of
developing liver fibrosis over time. Additionally, the MASH Cohort and other
similar cohort shave identified many factors independent factors associated with
liver fibrosis; including: HIV viral infection, ART use, substance abuse,
micronutrient status, food insecurity, and metabolic health. The development of a
liver fibrosis risk score that combines fibrosis risk factors into a single index could
be a convenient tool for health practitioners to use in determine fibrosis risk in
PLWH. Lastly, the impact of TyG and TyG Risk on mortality risk, would provide
an excellent insight into the overall impact of the TyG Index and metabolic health
overall on health outcomes in PLWH.
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